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Anesthetics are commonly used to induce unconsciousness and insensateness during surgery. 
However, the impacts of anesthetics on brain function go well beyond their acute 
pharmacological effects. Animal research suggests that the developing brain is particularly 
vulnerable to anesthesia, and even a single exposure may induce persistent neurobiological 
and behavioral consequences. Nevertheless, anesthetics have demonstrated remarkable 
therapeutic potential against some prevalent and debilitating brain disorders, especially major 
depression. Indeed, a single subanesthetic dose of ketamine has been reproducibly shown to 
alleviate depression and suicidal thinking within hours of administration, and the effects can 
last for days. Induction of brain-derived neurotrophic factor (BDNF) receptor TrkB signaling 
and synaptic plasticity have been intimately connected with ketamine’s antidepressant effects, 
but the precise mechanistic basis remains obscure. Notably, rapid antidepressant effects have 
also been reported with other anesthetics, including nitrous oxide (N2O) and isoflurane, and 
after somatic treatments such as electroconvulsive therapy (ECT) and sleep deprivation. 
In the first part of this thesis, we investigated the long-term behavioral effects of early 
postnatal exposure to repeated brief isoflurane anesthesia. We exposed mouse pups to 
anesthesia on three consecutive days at two distinct developmental stages, at postnatal days 7–
9 or 15–17, and later tested the behavioral phenotype of the adult animals. Isoflurane 
anesthesia caused modest behavioral effects on locomotor activity and spatial learning and 
memory of the adult mice, depending on the age of the animals during the anesthesia 
exposures.  
In the second part, we investigated the effects of various anesthetics on depressive-
like behavior and molecular signatures connected to the antidepressant effects of ketamine in 
rodents. We subjected rats to the chronic mild stress model of depression and subsequently 
exposed them to repeated brief isoflurane anesthesia for a total five times every three days.  
This administration regimen, however, was insufficient to normalize anhedonic behavior in 
the stressed rats. Cortical and hippocampal BDNF levels in these rats also remained unaltered.  
We then investigated the dose-dependent and temporal effects of different anesthetics 
on TrkB signaling, activity-dependent immediate-early genes (IEGs), and 
electroencephalographic (EEG) activity in mice. Here, we discovered that N2O upregulated 
several IEGs (markers of cortical excitation) during acute pharmacological effects, and that 
these effects were followed by a rebound emergence of EEG slow-wave activity (SWA) and 
TrkB signaling after treatment cessation. Similar concurrent upregulation of SWA and TrkB 
signaling was evident after a flurothyl-induced seizure (reminiscent of ECT) and during the 
effects of a sedative drug, medetomidine. Medetomidine, however, lacked antidepressant-like 
effects in the learned helplessness model of depression. This suggested that instead of only an 
increase in SWA and TrkB signaling, a preceding excitatory effect is also crucial for rapid 
antidepressant effects. This may also explain our observed lack of behavioral effects of deep 
isoflurane anesthesia. Moreover, even though ketamine’s antidepressant effects are associated 
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with subanesthetic doses, we found that ketamine increases SWA and TrkB signaling, with the 
most pronounced effects observed at high anesthetic-sedative doses. These effects appear 
independent of hydroxynorketamine, an active metabolite of ketamine that has demonstrated 
antidepressant-like effects in rodents.  
In conclusion, we found subanesthetic ketamine, N2O, and flurothyl to induce SWA 
after their acute pharmacological effects subsided. Interestingly, this phenomenon resembles 
the well-known postictal (i.e., after seizure) slowing of EEG activity, which has been 
connected to the antidepressant effects of ECT. Furthermore, the emergence of SWA coincided 
with the upregulation of TrkB signaling. Based on our results, we propose that rapid-acting 
antidepressants induce two distinct phases in the brain, with an initial excitatory phase 
followed by a sedative-like brain state that is characterized by SWA and TrkB signaling. 
Further studies are needed to elucidate whether a similar phenomenon is shared by other 
treatments that have demonstrated rapid antidepressant effects (e.g., isoflurane, psilocybin). 
The current proposal provides a novel framework for future research that encourages 
expanding the research focus from the acute pharmacology of the treatments to homeostatic 




























Anesteetit ovat pitkään olleet merkittävä osa kliinistä lääketiedettä, mutta ymmärryksemme 
niiden pitkäaikaisvaikutuksista on yhä puutteellista. Erityistä huolta ovat herättäneet 
varhaiskehityksen aikaista anestesiaa käsitelleet eläintutkimukset, joissa jo yksittäisen 
altistuksen on näytetty aiheuttavan pitkäkestoisia neurobiologisia ja käyttäytymistason 
muutoksia. Toisaalta, anesteeteilla on myös havaittu terapeuttista potentiaalia psykiatristen 
sairauksien, erityisesti masennuksen hoidossa aikuisilla. Eniten huomiota on saanut ketamiini, 
jonka on osoitettu lievittävän masennusoireita ja itsetuhoista ajattelua jo tuntien sisään 
yksittäisestä subanesteettisesta annostelusta, vaikutusten kestäessä parhaillaan yli viikon. 
Näiden vaikutusten neurobiologinen tausta on yhä osin epäselvää, mutta niiden ajatellaan 
liittyvän aivoperäisen hermokasvutekijän (BDNF) TrkB-reseptorin välittämiin aivojen 
muovautuvuuden muutoksiin. Myös muiden anesteettien, kuten isofluraanin ja ilokaasun, sekä 
somaattisten hoitojen kuten sähköhoidon ja unideprivaation on osoitettu lievittävän 
masennusoireita nopeasti.  
Tämän väitöskirjan ensimmäisessä osiossa tutkimme varhaisen isofluraanialtistuksen 
pitkäkestoisia käyttäytymisvaikutuksia altistamalla hiiriä kolmelle päivittäiselle 
isofluraanianestesialle kahdessa eri aikapisteessä varhaiskehityksen aikana, 7–9 tai 15–17 
päivän ikäisinä. Myöhemmin testasimme eläinten käyttäytymisfenotyyppiä aikuisiällä. 
Varhaiskehityksen aikainen toistettu isofluraanialtistus aiheutti lieviä muutoksia aikuisten 
hiirten lokomotorisessa aktiivisuudessa sekä heikennyksiä muistia ja oppimista mittaavissa 
testeissä. Vaikutukset riippuivat kehityksellisestä aikapisteestä, jona hiiret altistettiin 
anestesialle.  
Toisessa osiossa tutkimme anesteettien masennuslääkevaikutuksia sekä niiden 
aiheuttamia muutoksia ketamiinin masennuslääkevasteeseen liitettyihin neurobiologisiin 
tekijöihin aikuisilla jyrsijöillä. Ensin testasimme toistetun syvän isofluraanianestesian kykyä 
normalisoida kroonisen lievän stressimallin aiheuttamia käyttäytymismuutoksia rotilla. 
Viidesti toistettu isofluraanianestesia joka toinen päivä ei kuitenkaan lievittänyt masennuksen 
kaltaista käyttäytymistä stressille altistetuissa rotissa. Isofluraanilla ei myöskään ollut 
vaikutusta rottien etuaivokuoren tai hippokampuksen BDNF-pitoisuuteen. Seuraavaksi 
tutkimme anesteettien annosriippuvaisia vaikutuksia hiirten aivojen sähköiseen aktiivisuuteen 
elektroenkefalografian (EEG) avulla sekä TrkB:n välittämään solusignalointiin ja aivokuoren 
eksitaatiomarkkereihin annostelun eri vaiheissa. Havaitsimme ilokaasun lisäävän aivokuoren 
eksitaatiota välittömien farmakologisten vaikutusten aikana, kun taas annostelun lopettamisen 
jälkeen havaitsimme EEG:ssä hidasaalto-oskillaatioiden asteittaisen lisääntymisen, jonka 
aikana myös TrkB-signalointi aktivoitui. Havaitsimme samankaltaisen 
hidasaaltoaktiivisuuden ja TrkB-signaloinnin yhteisen esiintymisen myös flurotyylillä 
aiheutettujen kouristusten jälkeen (lääkkeellinen malli sähköhoidosta) sekä sedatiivisen 
lääkeaine medetomidiinin vaikutusten aikana. Medetomidiini ei kuitenkaan lievittänyt 
masennuksen kaltaista käytöstä opittu avuttomuus -hiirimallissa. Ketamiini lisäsi 
hidasaaltoaktiivisuutta ja TrkB-signalointia annosriippuvaisesti siten, että näiden esiintyvyys 
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oli voimakkainta anesteettisella annoksella, vaikka ketamiinin masennuslääkevaikutus 
ilmenee tyypillisesti subanesteettisella annoksella. Nämä vaikutukset olivat riippumattomia 
hydroksinorketamiinista – ketamiinin aktiivisesta metaboliitista, jolla on myös havaittu 
masennuslääkevaikutusta eläinkokeissa. 
Tuloksemme viittaavat siihen, että nopeavaikutteisten masennuslääkkeiden 
aikaansaamalla akuutilla eksitaatiolla ja sitä seuraavalla hidasoskillaatiotilalla on tärkeä 
merkitys niiden terapeuttisen vasteen kannalta. Tämä kaksivaiheinen ilmiö muistuttaa 
sähköhoidon jälkeen havaittavaa EEG-aktiivisuuden hidastumista, jonka voimakkuus on 
yhdistetty hoidon terapeuttiseen vasteeseen. Tätä taustaa vasten jatkotutkimuksissa tulisikin 
selvittää, tapahtuuko samanlainen ilmiö myös muiden nopeavaikutteista 
masennushoitovastetta osoittaneiden käsittelyjen, kuten isofluraanin ja psilosybiinin 
yhteydessä. Tuloksemme tarjoavat nopeavaikutteisten masennuslääkkeiden mekanistiseen 
tutkimukseen uuden lähestymiskulman, joka kannustaa tarkastelemaan hoitojen vaikutuksia 
niiden akuuttia farmakologiaa laajemmin myös lääkkeen eliminaation jälkeen ilmenevien 
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Major depressive disorder (MDD) is among the most prevalent mood disorders, affecting 
almost 350 million individuals worldwide (Smith, 2014). The high prevalence and debilitating 
symptoms make MDD one of the largest contributors to the global disease burden (Olesen et 
al., 2012; Wang et al., 2003). Depression is also one of the most common causes of early 
retirement and suicide. The complexity and heterogeneity of MDD poses a particularly 
difficult challenge for the study of the disease pathophysiology. 
 
Standard treatments for MDD include psychotherapy and monoaminergic antidepressants, 
such as tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs). However, 
the clinical efficacy of these drugs is limited, and their antidepressant effects commonly 
emerge only after weeks of treatment (Insel & Wang, 2009; Rush et al., 2006). This poses a 
particularly serious problem if the patient is at an acute risk of suicide. Furthermore, 
approximately one third of patients do not achieve clinical remission with prescription 
antidepressants. Despite decades of drug development, electroconvulsive therapy (ECT) has 
remained the most potent antidepressant treatment option since its introduction in the treatment 
of psychiatric disorders in the 1930s (Lisanby, 2007). The use of ECT, however, is associated 
with cognitive side effects, and has only limited availability due to the need for an inpatient 
treatment setting. ECT treatment typically also requires several weekly administrations to 
achieve and maintain its therapeutic effect, although more rapid antidepressant effects have 
been observed (Fligelman et al., 2016; Petrides et al., 2011). Sleep deprivation is another 
somatic treatment known to rapidly alleviate depressive symptoms. The antidepressant effects 
of sleep deprivation are considerably transient, and the symptoms commonly re-emerge after 
a subsequent sleep period (Giedke & Schwärzler, 2002; Wu & Bunney, 1990). There is, 
therefore, a substantial unmet medical need for novel, more effective, and rapidly acting 
antidepressants with more sustainable therapeutic effects. Interestingly, increasing evidence 
suggests that diverse anesthetic agents hold such potential. 
 
Anesthetics produce dose-dependent insensateness and loss of consciousness, and they have 
been widely used in different medical operations (e.g., surgery) since the 19th century 
(Campagna et al., 2003). While anesthetics are generally considered safe and well tolerated, 
anesthesia, particularly during early development, has been associated with neuroapoptosis 
and learning disabilities later in life, raising concerns about its safety for juveniles (Wilder et 
al., 2009). In adult patients, however, emerging clinical evidence suggests that brief anesthesia 
may rapidly alleviate depressive symptoms (Tadler & Mickey, 2018). Putative rapid 
antidepressant effects of anesthesia have been investigated since the 1980s, encouraged by the 
association of the postictal (i.e., after seizure) slowing of electroencephalogram (EEG) activity 
(a typical electrophysiological signature during anesthesia), and the antidepressant effects of 
ECT (Langer et al., 1985; Sackeim et al., 1996). Deep burst-suppressing isoflurane anesthesia 
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demonstrated rapid antidepressant effects in the early small-scale clinical trials, but the 
subsequent findings remained inconsistent (Carl et al., 1988; Greenberg et al., 1987; Langer et 
al., 1985, 1995). However, recent clinical and preclinical findings have renewed the interest in 
the antidepressant effects of deep anesthesia (Antila et al., 2017; Brown et al., 2018a; Mickey 
et al., 2018; Weeks et al., 2013).  
 
A major breakthrough in antidepressant treatment emerged at the beginning of the millennia 
when the rapid antidepressant effects of ketamine were discovered (Berman et al., 2000). 
Ketamine is a dissociative anesthetic targeting the N-methyl-D-aspartate receptors (NMDAR), 
but its antidepressant effects become evident particularly at low subanesthetic doses (Berman 
et al., 2000; Zarate et al., 2006a). Remarkably, the positive effects of ketamine on the core 
symptoms of depression emerge within hours after administration, with peak effects 
commonly observed a day after drug delivery. In 2019, an intranasal formulation of (S)-
enantiomer of ketamine (esketamine) received approvals from the U.S. Food and Drug 
Administration and the European Medicines Agency for use as an adjunct to oral 
antidepressants in the treatment of depression. However, the antidepressant effects of ketamine 
are usually short-lived, lasting typically only up to a week. The clinical use of ketamine in 
psychiatry is further limited by its acute psychotomimetic effects and misuse potential. 
 
Several hypotheses have been proposed to underlie the antidepressant effects of ketamine, but 
the precise cellular and neurobiological mechanisms remain debated. A deeper understanding 
of the neurobiological basis of rapid antidepressant action would undoubtedly provide new 
tools for the development of more rapid-acting, safe, and effective antidepressant treatment 
options. In this literature review, I summarize the current knowledge regarding mechanisms 
of diverse rapid-acting antidepressants and discuss the effects of anesthesia on neuronal 

















2. Review of the literature  
 
2.1. Major depressive disorder — need for rapid-acting 
antidepressants 
 
Major depressive disorder is a highly prevalent and debilitating mood disorder. Nearly one in 
six individuals suffers from MDD during their lifetime in the US (Kessler et al., 2003). Typical 
symptoms of MDD include persistently depressed mood, anhedonia, low self-esteem, feelings 
of worthlessness, and impaired sleep, appetite, and sexual function (Nestler et al., 2002). MDD 
has a high comorbidity with many other psychiatric disorders, including anxiety and substance 
abuse (Kessler et al., 2003), and also with various other diseases, such as cardiovascular 
disease and type 2 diabetes (Knol et al., 2006; Musselman et al., 1998). MDD is a multifactorial 
and heterogenous disorder, where patients express varying symptoms and responses to 
available treatments (Nestler et al., 2002). Therefore, instead of being a single disease, MDD 
has been proposed to consist of many syndromes with differing characteristic sets of causes 
and symptoms (Nestler et al., 2002).  
 
There are currently no sensitive and objective biomarkers of MDD. Instead, the disorder is 
diagnosed based on clinical assessment and symptomatology. Essentially, the diagnostic 
criteria, specified in the fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders requires the presence of five or more specified symptoms for at least two weeks 
(Otte et al., 2016). Common rating scales for depression severity include questionnaires 
through which the clinician rates the severity of the patient’s depression: a 17-item Hamilton 
rating scale for depression (Hamilton, 1960) and a 10-item Montgomery-Åsberg Depression 
Rating Scale (Montgomery & Åsberg, 1979).  
 
Our understanding of MDD pathophysiology remains limited, but both genetic and 
environmental risk factors seem to be involved. Genetic predisposition plays a role in 
susceptibility for MDD, although no particular genes have been consistently identified (López-
León et al., 2008; Sullivan et al., 2000). MDD is also nearly twice as common in women than 
in men, but the neurobiological factors contributing to this risk remain unknown (Kessler et 
al., 1993). Stressful life events and emotional trauma pose a major risk factor for developing 
MDD (Kendler et al., 1999; Nestler et al., 2002; Vythilingam et al., 2002). First depressive 
episodes most commonly emerge between mid-adolescence and the mid-40s, with the majority 
of patients experiencing their first episode before their mid-20s (Malhi & Mann, 2018).  
 
Imaging studies have identified specific neuropathological changes and neuronal circuits to be 
associated with MDD (Drevets, 2000; Sheline, 2003). Structural abnormalities have been 
observed, particularly in the highly interconnected limbic regions of the brain that regulate 
emotional processing and reward. Alterations in neuronal and glial morphology and decreased 
volume in specific prefrontal and hippocampal regions in depressed patients are commonly 
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reported (Bremner et al., 2000; Coffey et al., 1993; Drevets et al., 1997; Frodl et al., 2002; 
Mervaala et al., 2000; Rajkowska et al., 1999; Schmaal et al., 2017; Sheline et al., 2003). In 
addition, alterations in neuronal network connectivity, dysfunction of the hypothalamic-
pituitary-adrenal axis, and increased cytokine levels have been consistently observed 
(Rosenblat et al., 2014). 
 
Despite our limited knowledge of depression pathophysiology, several forms of treatments are 
available. Cognitive and behavioral psychotherapy may be sufficient in the treatment of mild-
to-moderate depression, but various antidepressant drugs are also widely used (Nestler et al., 
2002). Discovery of the antidepressant effects of imipramine and iproniazid, initially studied 
in the 1950s in the treatment of allergic symptoms and tuberculosis, respectively, paved the 
way for the current prescription antidepressants (Castrén, 2005). Both imipramine and 
iproniazid were shown to increase monoaminergic neurotransmission, especially serotonergic 
and noradrenergic, by either blocking the reuptake of serotonin and noradrenaline to 
presynaptic nerve endings or by inhibiting the function of monoamine oxidase, an enzyme 
responsible for monoamine breakdown. Antidepressants that were developed following these 
findings include tricyclic antidepressants (e.g., amitriptyline), monoamine oxidase A inhibitors 
(MAOIs, e.g., moclobemide), SSRIs (e.g., fluoxetine, citalopram), selective serotonin and 
noradrenaline reuptake inhibitors (e.g., venlafaxine), and agomelatine. Similarly to 
imipramine and iproniazid, these drugs mainly act by increasing the availability of serotonin 
and/or noradrenaline in the synaptic cleft. Agomelatine is a notable exception in that it 
functions as an antagonist on serotonin receptor subtypes 5-HT2B and 5-HT2C and as an agonist 
on melatonin receptors MT1 and MT2 (San & Arranz, 2008). More recently developed 
antidepressant drugs have fewer side effects than the initial tricyclic antidepressants, but the 
overall efficacy of antidepressants has not significantly improved upon introduction of these 
new compounds (Nestler et al., 2002). Importantly, about one third of patients remain resistant 
to treatment with classical antidepressants, emphasizing an unmet medical need for better 
treatment options (Insel & Wang, 2009). 
 
The clinical antidepressant effects of drugs that enhance monoaminergic neurotransmission 
led to the formulation of a monoamine hypothesis of depression that postulates disturbances 
in monoaminergic neurotransmission to underlie the condition (Schildkraut, 1965). However, 
accumulating clinical and preclinical findings have made it obvious that mere monoamine 
deficiency is insufficient to explain the pathophysiology of depression and antidepressant 
action (Krishnan & Nestler, 2008; Manji et al., 2001). Indeed, reduced monoamine function 
does not consistently produce depressive symptoms in healthy people (Booij et al., 2003). 
Moreover, monoaminergic antidepressants cause an acute effect in monoaminergic 
neurotransmission, while the impact on the core symptoms of depression emerges only 
gradually after chronic treatment (Nestler et al., 2002). Therefore, much of the later research 
efforts have focused on the long-term neurobiological adaptations induced by antidepressants. 
Here, the effects of antidepressants on neurotrophic signaling, particularly those regulated by 
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the brain-derived neurotrophic factor (BDNF), have provided a more thorough understanding 
of the long-term effects of antidepressants.   
 
2.2. BDNF and antidepressant action 
 
2.2.1. Basic neurobiology of BDNF 
 
BDNF belongs to the neurotrophin family of neurotrophic factors (Autry & Monteggia, 2012; 
Park & Poo, 2013; Thoenen, 1995). Other neurotrophic factors in this family are nerve growth 
factor and neurotrophins 3 and 4. BDNF is the most prevalent neurotrophin in the mammalian 
brain, and its expression is tightly regulated by neuronal activity (Thoenen, 1995). It is an 
important promoter of neuronal survival, growth, differentiation, and maturation in the 
developing brain, and a key regulator of neuroplasticity in the adult brain (Park & Poo, 2013). 
Neuroplasticity refers to the adaptive ability of the brain to change in response to extrinsic and 
intrinsic stimuli. In the adult brain, this is mainly achieved by activity-dependent modulation 
(i.e., strengthening or weakening) of synaptic connections or the formation of new connections 
through synaptogenesis. These mechanisms are involved in the formation of functional 
synapses during early development, but they are also proposed to be involved in learning and 
memory processes in adulthood (Lu et al., 2008). Neuroplastic changes may also include 
neurogenesis, that is, the formation of new neurons. However, in the adult brain, neurogenesis 
is limited to markedly few brain areas: the subventricular zone of lateral ventricles and the 
subgranular zone of the dentate gyrus (Zhao et al., 2008). 
 
In the developing brain, BDNF promotes neuronal survival by initiating intracellular signaling 
pathways that protect neurons from apoptosis (Reichardt, 2006). During axon-dendrite 
differentiation of developing neurons, BDNF has been shown to promote neurite 
differentiation into an axon (Shelly et al., 2007). Furthermore, BDNF secretion from target 
tissue guides neurite outgrowth (Autry & Monteggia, 2012). Involvement of BDNF in adult 
neurogenesis has been demonstrated in rats by hippocampal infusion of BDNF, which 
increased the number of adult-born neurons in the subgranular zone (Scharfman et al., 2005). 
BDNF has been shown to stimulate the formation of functional excitatory and inhibitory 
synapses in vitro (Vicario-Abejón et al., 1998). It has also been strongly implicated in long-
term potentiation (LTP), a form of activity-dependent strengthening of synaptic function 
considered to underlie learning and memory (Lu et al., 2008). Various studies have 
demonstrated that LTP induced by high-frequency stimulation of neurons is strengthened in 
the presence of exogenous BDNF and weakened when normal BDNF function is disturbed 
(Figurov et al., 1996; Korte et al., 1995; Minichiello et al., 2002). 
 
The crucial role of BDNF in neuronal development is further emphasized by observations 
made in knockout rodents. Homozygous deletion of the BDNF encoding gene in mice leads to 
severe abnormalities in brain development (Ernfors et al., 1994). These mice express 
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widespread neuronal atrophy and deficits in peripheral neuronal innervation. The full knockout 
rodents die soon after birth, mainly before the second postnatal week, due to cardiac and 
respiratory problems (Erickson et al., 1996; Ernfors et al., 1994). However, further insight into 
the role of BDNF in the adult brain has been obtained from conditional and inducible BDNF 
knockout mouse models. These models allow deletion of BDNF in a regionally and temporally 
specific manner, thereby circumventing lethal developmental abnormalities caused by 
conventional BDNF knockout (Monteggia et al., 2004; Rios et al., 2001). Conditional BDNF 
knockout in post-mitotic neurons of mice leads to a substantial postnatal reduction of BDNF 
in cortical, hypothalamic, and hippocampal regions (Rios et al., 2001). The conditional 
knockout animals express an increase in anxious behavior, food intake, and body weight. In 
contrast, mice with inducible BDNF deletion in post-mitotic neurons of broad forebrain 
regions demonstrate impairments in hippocampal-dependent learning and memory, both when 
the deletion is timed in early development and in adulthood (Monteggia et al., 2004). The same 
study also found the inducible BDNF knockout during early life to result in hyperactive 
behavior of the adult mice.  
 
Additional information on the role of BDNF is provided by naturally occurring single 
nucleotide polymorphisms in the Bdnf gene. The Val66Met polymorphism that substitutes 
valine to methionine at codon 66 (BDNFVal66Met) is of particular interest as it has been shown 
to impair intracellular trafficking and activity-dependent secretion of BDNF without altering 
the total levels of BDNF in the brain (Chen et al., 2004, 2006; Egan et al., 2003). The Met 
allele, which nearly a third of the world’s population is estimated to carry (Chen et al., 2006), 
has been associated with modest memory impairments and decreased hippocampal volume in 
humans (Egan et al., 2003; Hajek et al., 2012). In rodents, BDNFVal66Met polymorphism has 
been associated with decreases in hippocampal volume and increased anxiety-like behavior in 
open field and elevated plus-maze (EPM) tests, with Met/Met homozygotes demonstrating 
more significant perturbations than Val/Met heterozygotes (Chen et al., 2006).  
 
BDNF is initially synthesized as a precursor form, pro-BDNF, which may then undergo 
proteolytic cleavage to mature BDNF (Park & Poo, 2013). BDNF exerts its diverse effects 
through binding to its high-affinity tropomyosin-related kinase B (TrkB) receptor tyrosine 
kinase (Huang & Reichardt, 2001; Takei et al., 2001). Binding of a BDNF dimer to membrane-
bound TrkB receptors induces receptor dimerization that leads to autophosphorylation of 
several tyrosine (Y) residues in the intracellular tyrosine kinase domain of the receptors, 
including Y515 and Y816 residues (Minichiello, 2009). Phosphorylation of these tyrosine 
residues further leads to recruitment of adaptor proteins and activation of intracellular 
signaling cascades involved in cell survival, differentiation, and plasticity. These include the 
phospholipase Cγ (PLCγ), the mitogen-activated protein kinase (MAPK), and the 
phosphatidylinositol 3-kinase (PI3K) pathways (Figure 1). Activation of the PLCγ pathway 
by phosphorylation of the Y816 site generates the second messengers inositol trisphosphate 
(IP3) and diacylglycerol (DAG) (Finkbeiner et al., 1997). IP3 releases intracellular Ca2+ from 
the endoplasmic reticulum that can then activate calcium/calmodulin-dependent protein kinase 
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IV (CaMKIV)-dependent signaling and protein synthesis through the transcription factor 
cyclic AMP response element binding protein (CREB). CREB can also be phosphorylated by 
sequential activation of the small G protein Ras and protein kinases MAPK and Rsk, following 
TrkB activation (Huang & Reichardt, 2001). The PI3K pathway, activated by TrkB 
phosphorylation in the Y515 site, leads to downstream activation of protein kinase B (Akt) 
and mammalian target of rapamycin (mTOR), a major modulator of protein translation, which 
exerts its translational control through phosphorylation of kinases 4EBP1 and p70S6K further 
downstream (Takei et al., 2004).  
 
BDNF can also bind to the truncated form of TrkB receptor TrkB.T1 (Park & Poo, 2013). 
TrkB.T1 lacks the intracellular tyrosine kinase domain, and hence works as a dominant 
negative regulator of TrkB signaling. Moreover, pro-BDNF can elicit TrkB-independent 
signaling by binding to the p75 neurotrophin receptor (p75NTR) (Autry & Monteggia, 2012). 
Signaling initiated by p75NTR regulates cellular responses opposite to those regulated by 
TrkB, including neuronal apoptosis (Bamji et al., 1998; Friedman, 2000). Therefore, the 





Figure 1. Intracellular signaling mechanisms activated by TrkB neurotrophin receptor. 
PI3K, MAPK and PLCγ signaling pathways are activated by the dimerization and subsequent 
autophosphorylation of TrkB. The pathways influence diverse neuronal functions, such as cell 
survival, and transcription and translation of synaptic proteins.  
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2.2.2. Neurotrophin hypothesis of depression 
 
Accumulating evidence suggests that alterations in BDNF signaling play a major role in 
depression pathophysiology and antidepressant function. Various findings have contributed to 
the formulation of a neurotrophic hypothesis of antidepressant action (Duman et al., 1997; 
Duman & Monteggia, 2006). The hypothesis postulates that a deficiency in neurotrophic 
support that results in neuronal atrophy and circuit dysfunction underlies depression 
pathophysiology, and that antidepressant drugs act by reversing these deficiencies. This 
hypothesis is supported by a large body of experimental findings reviewed here. 
 
Brain imaging studies have revealed various structural and morphological abnormalities in the 
brain to be associated with MDD (Price & Drevets, 2010). In particular, decreased gray matter 
volume in specific cortical and limbic areas has been consistently reported in depressed 
patients (Drevets et al., 1997; Rajkowska et al., 1999; Sheline, 2003). In rodents, exposure to 
chronic stress and other depression models has produced atrophic morphological alterations in 
cortical areas and the hippocampus (HC) reminiscent of those observed in depressed patients 
(Li et al., 2011; Liu & Aghajanian, 2008; McEwen, 2005; Moda-Sava et al., 2019).  
 
Various stressors, such as repeated immobilization stress, foot shocks, and unpredictable 
chronic mild stress (CMS) have been shown to decrease Bdnf mRNA expression in the rodent 
HC and prefrontal cortex (PFC) (Nibuya et al., 1999; Rasmusson et al., 2002; Smith et al., 
1995). In humans, decreased BDNF levels have been measured in the serum of depressed 
patients and in the PFC and HC of suicide victims (Dwivedi et al., 2003; Karege et al., 2002). 
Moreover, the Met allele has been associated with a higher susceptibility for MDD, although 
contrasting findings have also been reported (Gatt et al., 2009; Jiang et al., 2005).  
 
Monoaminergic antidepressants have been consistently shown to induce synaptic plasticity 
and neurogenesis in the adult central nervous system (CNS), stimulating research interest in 
the role of BDNF in antidepressant treatment (Duman et al., 2016; Rantamäki & Yalcin, 2016). 
Chronic—but not acute— administration of various antidepressants, including fluoxetine and 
reboxetine, induced neurogenesis in the rat HC (Malberg et al., 2000). A further study reported 
hippocampal neurogenesis to be necessary for the antidepressant effects of fluoxetine, since a 
disruption of neurogenesis by hippocampal irradiation abolished the antidepressant-like 
behavioral effects in the novelty suppressed feeding test in mice (Santarelli et al., 2003). 
Regulation of BDNF expression has been strongly implicated in the antidepressant effects of 
classical antidepressants. Chronic—but not acute— administration of diverse monoaminergic 
antidepressants, including imipramine and sertraline, for 21 days increased the expression of 
Bdnf and TrkB mRNA in the rat HC (Nibuya et al., 1995). Increased hippocampal Bdnf 
expression was also reported after only two days of tranylcypromine (MAOI) treatment 
(Russo-Neustadt et al., 2000). The effects were even more pronounced after a one-week 
chronic administration. Diverse antidepressants, including imipramine, fluoxetine, and 
citalopram, were also shown to acutely increase TrkB phosphorylation in the rodent HC and 
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cortical regions (Rantamäki et al., 2007; Saarelainen et al., 2003). Furthermore, post-mortem 
brain tissue collected from depressed subjects treated with antidepressants showed increased 
BDNF expression in various hippocampal regions (Chen et al., 2001).  
 
More direct evidence for the importance of BDNF in antidepressant effects is provided by 
studies demonstrating that intrahippocampal and intracerebroventricular infusions of BDNF 
produce antidepressant-like behavioral effects in the forced swim test (FST) and the learned 
helplessness model in rodents (Hoshaw et al., 2005; Shirayama et al., 2002; Siuciak et al., 
1996). Several reports have also indicated normal BDNF and TrkB function to be necessary 
for an antidepressant-like behavioral response to monoaminergic antidepressants in rodents. 
Disruption of regular TrkB signaling by an overexpression of the dominant negative TrkB.T1 
isoform in postnatal cortical and hippocampal neurons abolished antidepressant-like 
behavioral effects of fluoxetine and citalopram in the mouse FST (Rantamäki et al., 2007; 
Saarelainen et al., 2003). In addition, viral vector-mediated localized BDNF knockout in the 
mouse HC resulted in a loss of antidepressant-like behavioral effects of classical antidepressant 
drugs desipramine and citalopram in FST (Adachi et al., 2008). Furthermore, conditional 
deletion of the TrkB encoding gene in neural progenitor cells but not in differentiated cells in 
the mouse dentate gyrus abolishes the antidepressant-like behavioral responses of chronic 
fluoxetine and imipramine administrations, indicating a crucial role for TrkB-mediated 
hippocampal neurogenesis in antidepressant response (Li et al., 2008). 
 
Overall, these findings support the idea postulated in the neurotrophic hypothesis of depression 
proposing that diminished neurotrophic support underlies depressive symptoms, whereas 
antidepressants function by renormalizing this imbalance. However, depression etiology likely 
exceeds mere chemical imbalance in the brain, be it monoamines or neurotrophins, and the 
focus of antidepressant research has lately expanded its scope to understand the potential 
functional benefit of antidepressants’ ability to regulate neuroplasticity. 
 
2.2.3. Network hypothesis of depression 
 
Despite BDNF being acknowledged as a crucial mediator of neuroplasticity in the brain, the 
diverse manners through which the brain changes can hardly be considered to stem from the 
expression of a single molecular entity. Instead, synaptic and neuronal plasticity involves 
activity-dependent morphological and functional changes in neuronal networks that are 
influenced by environmental input (Hensch, 2005). These aspects are taken into consideration 
in a proposed network hypothesis of depression that suggests disturbances in the information 
processing of neuronal circuits underlie depression (Castrén, 2005; Castrén & Rantamäki, 
2010). This hypothesis postulates that antidepressants elicit their therapeutic effects by 
enabling a gradual functional reorganization of pathologically affected circuits through 
activity-dependent modifications in neuronal networks.  
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The mammalian primary visual cortex has been extensively utilized to provide insight into 
activity-dependent functional neuroplasticity and the network hypothesis of depression. The 
visual system is particularly vulnerable to experimental manipulations as animals are relatively 
easy to partially or completely deprive of visual stimulus by suturing an eyelid shut or by 
manipulating surrounding illumination (e.g., by dark rearing). Indeed, monocular deprivation 
during a specific temporal window during early postnatal development can cause a severe and 
persistent deficit in vision (i.e., amblyopia) in the deprived eye due to improper visual input 
(Hensch, 2005; Wiesel & Hubel, 1963). The lack of stimulus from the deprived eye results in 
a shift in ocular dominance distribution of the visual cortex in favor of the open eye, thereby 
functionally disconnecting the deprived eye from the visual cortex. Monocular deprivation 
does not have similar effects when applied outside a specific developmental window of 
heightened plasticity (i.e., sensitive period). 
 
The amblyopia model has provided remarkable insight into antidepressant function, supporting 
the network hypothesis. Chronic fluoxetine administration in combination with patching of the 
non-amblyopic eye (cf. rehabilitation), but neither alone, restored vision both behaviorally 
(visual acuity) and functionally (visually evoked potentials in the visual cortex) in an 
amblyopic eye in adult rats (Maya-Vetencourt et al., 2008). These effects were accompanied 
by increased BDNF expression in the visual cortex. The network hypothesis has also been 
tested using the fear conditioning paradigm (Karpova et al., 2011). Fear extinction training 
during early development has been shown to bring permanent erasure of fear memory, while, 
in adult animals, the effects are more transient and vulnerable to renewal (Kim & Richardson, 
2010). However, chronic fluoxetine administration in combination with extinction training 
resulted in a more effective erasure of fear memory and absence of fear renewal than either of 
the treatments alone (Karpova et al., 2011). The same study found the effects to be absent in 
heterozygous BDNF+/- mice. These findings suggest that fluoxetine can reinstate a juvenile-
like form of neuronal plasticity, even in the adult brain. 
 
In light of our understanding of depression as a gradually developing disorder, it is logical to 
assume that antidepressant treatments also require weeks for the therapeutic effects to manifest 
(O’Leary et al., 2014). The network hypothesis provides a plausible basis for antidepressants’ 
delayed onset of action. This is because BDNF-induced changes in synaptic plasticity and 
activity-dependent rewiring of neuronal connections require slowly developing adaptations 
before the effects on complex behaviors and mood become evident. Notably, the network 
hypothesis also helps to explain why psychotherapy and antidepressant medication provide a 
more effective therapeutic response in combination as the hypothesis emphasizes the 
importance of external stimulus in addition to the acute drug effects (Pampallona et al., 2004). 
However, these views are challenged by the surprisingly rapid alleviation of depressive 
symptoms that can be achieved with some treatments. These methods include somatic 
treatments, such as ECT and sleep deprivation, but various pharmacological options have also 
emerged. Interestingly many of these are anesthetics. 
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2.3. Diverse developmental stage-dependent effects of anesthesia 
 
The discovery of anesthesia revolutionized clinical medicine, allowing complex surgical 
procedures while the patient remains disconnected from painful stimulus (Franks, 2008). 
Anesthesia, by definition, produces reversible, dose-dependent loss of consciousness, 
analgesia, and insensateness. To achieve balanced surgical anesthesia, a multimodal approach 
is used in which anesthetic compounds are co-applied with antinociceptive agents, such as 
opioids, muscle relaxants, cardiovascular drugs, and ventilatory and thermoregulatory support 
(Brown et al., 2018b). This approach allows for sufficient depth of anesthesia while 
minimizing the required amount of a single drug, thereby decreasing the risk for drug-related 
side effects. Today, anesthesia is administered to tens of millions of people every year. 
However, as the use of anesthesia increases, so does our understanding of the diverse 
influences of anesthetics on brain function that exceed its conventional pharmacological 
effects. 
 
Anesthetics are a pharmacologically diverse class of compounds that primarily act by 
facilitating neuronal inhibition through GABAA receptor (GABAAR) function (e.g., isoflurane, 
sevoflurane) and/or suppressing neuronal excitation by inhibiting the glutamatergic NMDAR 
activity (e.g., ketamine, nitrous oxide) (Campagna et al., 2003). GABAA receptors are chloride 
ion permeable channels activated by gamma-aminobutyric acid (GABA), and are one of the 
main receptors responsible for inhibitory synaptic transmission in the adult brain. In addition 
to GABAARs and NMDARs, some anesthetics also inhibit glutamatergic α-amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid receptors (AMPARs), nicotinic acetylcholine receptors, 
and various ion channels. Moreover, α2-adrenergic autoreceptor agonists, such as 
(dex)medetomidine, have been introduced as an adjunct for general anesthesia due to their 
capability to produce anxiolysis, analgesia, and sedation (Correa-Sales et al., 1992). These 
compounds act by hyperpolarizing and decreasing the release of noradrenaline from locus 
coeruleus neurons, thereby inducing sleep-like sedation (Brown et al., 2011).  
 
In the spinal cord, an anesthetic-induced overall decrease in neuronal excitability reduces the 
transmission of noxious stimuli (Campagna et al., 2003). In the brain, anesthetics globally 
decrease cerebral blood flow and glucose metabolism, accompanied by a generalized slowing 
of EEG activity, that is, a power increase in low-frequency, high-amplitude delta oscillations 
(1–4 Hz). Anesthesia therefore shares many behavioral, functional, and EEG features with 
deep sleep, and the same subcortical networks that regulate sleep may be involved in anesthetic 
action as well (Brown et al., 2010). While it is notable that at low doses (e.g., during induction) 
anesthetics may induce paradoxical excitation, as the level of anesthesia deepens, low-
frequency, high-amplitude EEG oscillations increase. Increasing the depth of anesthesia 
eventually leads to a burst-suppressing EEG state, which is not observed under physiological 
sleep. Burst-suppression is a state characterized by alternating patterns of quiescent EEG 
activity followed by brief high-frequency bursting activity. 
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Most general anesthetics, such as volatile halogenated hydrocarbons (e.g., isoflurane, 
sevoflurane), have relatively short half-lives, which allows for rapid recovery following drug 
discontinuation (Campagna et al., 2003). General anesthetics are subject to hepatic 
metabolism, a notable exception being nitrous oxide (N2O), which is eliminated without 
significant metabolism through respiration (Nagele et al., 2018). Common side effects of 
general anesthetics include cardiopulmonary depression and emergence delirium upon 
anesthesia cessation. In addition, NMDAR antagonists, such as ketamine and N2O, are 
characterized by psychotomimetic effects that precede the anesthetic state (Franks, 2008). 
Moreover, brain activity during NMDAR antagonist anesthesia differs drastically from that 
observed with GABAA targeting anesthetics, as evidenced by their opposite effects on global 
cerebral blood flow and thalamic glucose metabolism (Långsjö et al., 2005). 
 
While general anesthetics were initially considered to be safe and well-tolerated compounds 
with reversible effects, accumulating evidence has shown that exposure to anesthetics, 
particularly during early stages of brain development, can cause long-lasting disturbances in 
neurocognitive function later in life (Vutskits & Xie, 2016). This is particularly alarming 
because millions of newborns are exposed to anesthetics every year. However, increasing 
evidence shows that the depth, duration, and time points of anesthesia exposure have a major 
influence on the potentially detrimental effects of anesthetics as several studies have 
demonstrated that in adults, anesthetics may even hold therapeutic potential against some 
disorders, including MDD (Vutskits, 2018). 
 
2.3.1. Anesthetics and the developing brain 
 
Early brain development is a carefully orchestrated and multi-staged process that progresses 
from the generation and proliferation of progenitor cells through the migration and 
differentiation of neurons and glia to the subsequent branching of axons and dendrites, and the 
eventual synaptogenesis and formation of neuronal networks that give rise to complex 
behaviors (Figure 2) (Andersen, 2003). The basis for the neuronal network structure is laid 
down during embryonic and fetal development through intrinsic developmental mechanisms, 
but the structural development of neuronal circuitry continues after birth and through 
adolescence in an experience- and activity-dependent manner (Hensch, 2004, 2005; Rice & 
Barone, 2000). 
 
Brain development generally follows similar sequences across different mammalian species, 
but the timing and speed of the process can vary dramatically between species (Clancy et al., 
2001). For instance, the formation of the neural tube, one of the first steps of CNS development 
in utero, occurs approximately halfway through a 3-week gestation in rodents, whereas in 
humans it takes place between embryonic weeks 3 and 4, approximately one month into a 9-
month gestation (DeSesso et al., 1999). Neural tube formation is followed by a sequence of 
developmental processes, such as cell proliferation, migration, differentiation, synaptogenesis, 
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and myelination, that take place over a timeline of days in rodents versus months in humans 
(Figure 2-3) (Rice & Barone, 2000). These interspecies differences provide a particular 
challenge in translating preclinical animal findings to humans. 
 
Figure 2. Phases of early brain development in humans. The structural basis of the brain is 
already formed during embryonic development, but the activity-dependent fine-tuning of 
neuronal networks continues throughout postnatal life and adolescence. Figure modified after 
Andersen (2003). 
 
During neurogenesis in embryonic development, neurons are initially overproduced and are 
eventually eliminated to about 50% of their initial amount through programmed cell death 
(Andersen, 2003). A similar event also occurs during postnatal synaptogenesis, when a 
significant number of synapses are formed, most of which are pruned out before adolescence 
(Huttenlocher, 1979). These morphological overshoots likely serve to enable activity-
dependent and selective elimination of redundant synaptic connections and strengthening of 
the remaining connections, thereby increasing the efficiency and selectivity of synaptic 
transmission (Andersen, 2003; Kano & Hashimoto, 2009). 
 
The developing brain is particularly susceptible to various disturbances, and many psychiatric 
disorders are believed to have a developmental origin (Andersen, 2003). Such disturbances 
include environmental, genetic, and pharmacological factors. These extrinsic factors are 
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especially influential during specific time windows of early development called sensitive 
periods (Hensch, 2004, 2005). Adversity-driven structural and functional alterations during 
these periods may have a permanent effect on neuronal circuit function. This phenomenon is 
particularly well demonstrated in the previously discussed visual cortex model, where a 
closure of one eye during a sensitive postnatal period leads to a permanent loss of vision in 
that eye (Section 2.2.3.). However, experiences during critical periods can have a significant 
impact on the acquisition and learning of a particular skill or behavior (Hensch, 2005). Since 
different brain areas mature at different stages of prenatal and postnatal development, they also 
have distinct temporal windows of opportunity and vulnerability. The brain retains some 
plasticity through adulthood but not in as high abundance as during sensitive periods, a notable 
example being the gradually decreasing ability of the brain to functionally recover from 
injuries (Feinberg, 1982). 
 
As the developmental processes in the brain are driven by environmental input in an activity-
dependent manner, anesthetics that significantly interfere with excitatory and inhibitory 
neurotransmission can disturb these processes, particularly during the early stages of postnatal 
brain development. Indeed, repeated exposure to anesthesia before the age of four years has 
been associated with increased risk for the development of learning disability later in life (Flick 
et al., 2011; Wilder et al., 2009). In rodents, long-term effects of early life anesthesia have 
been shown to vary depending on age of exposure (Briner et al., 2011). Exposure to anesthetics 
such as isoflurane and sevoflurane during the brain growth spurt at the first postnatal week has 
been consistently shown to produce increased apoptotic neurodegeneration in cortical, 
hippocampal, and thalamic areas in rodents (Jevtovic-Todorovic et al., 2003; Tagawa et al., 
2014). These effects were associated with sustained behavioral abnormalities in rats, as 
demonstrated in the Morris water maze test, which measures spatial navigation and memory 
in rodents (Shen et al., 2013). Ketamine (20–40 mg/kg, s.c.) induced neuroapoptosis in the 
caudate nucleus and cortex of mice dose-dependently only five hours after administration at 
postnatal day (P)7 (Young et al., 2005). Moreover, combinations of anesthetics have been 
shown to produce more deleterious effects than a single agent (Tagawa et al., 2014). Ketamine 
co-administered with propofol or thiopental induced neuroapoptosis 24 hours after 
administration in P10 mouse olfactory bulb and stria terminalis (Fredriksson et al., 2007). The 
treatments also elicited persistent disturbances in motor behavior, spatial learning, and 
memory when tested later at P55. Sevoflurane administered to rat pups at P7 caused a 
hippocampal synaptic loss that was more pronounced after repeated anesthesias (3 x 2 hours) 
than a single 2-hour anesthesia (Amrock et al., 2015). 
 
The rodent brain goes through rapid maturation during the first postnatal weeks. This is 
reflected in the contrasting effects of anesthesia at different developmental stages. In contrast 
to the neuroapoptotic effects of anesthesia during the first postnatal week, exposure of rats to 
anesthetics at P16 increased dendritic spine density instead (Briner et al., 2010; De Roo et al., 
2009). Furthermore, propofol decreased dendritic spine density when administered at P5 and 
P10, but increased it at P15, P20, and P30 (Briner et al., 2011). The effects were sustained until 
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the rats were up to 3 months old. Similar developmental stage-dependent effects were observed 
after brief sevoflurane anesthesia (Qiu et al., 2016). A 30-minute sevoflurane anesthesia 
(2.5%) induced a decrease in dendritic spine density in rat cortical pyramidal neurons when 
administered at P7 but an increase at P15. Neither of these alterations persisted into adulthood. 
Time-dependent alterations in isoflurane effect were also observed in organotypic 
hippocampal slices collected at different postnatal time points (Wise-Faberowski et al., 2005). 
Isoflurane (1.5%) exposure for 5 hours caused neurodegeneration in slices collected at P7 but 
not at P4 or P14. Developmental differences in anesthetic response have also been 
demonstrated in non-human primates. A 24-hour infusion of ketamine was reported to cause 
neuroapoptosis in the rhesus macaque frontal cortex at P5 but not at P35 (Slikker et al., 2007). 
Moreover, the same study reported that a 3-hour infusion of ketamine did not result in 
increased neuroapoptosis, even at P5, indicating the important role of the exposure duration in 
the apoptotic neurodegeneration. 
 
Overall, several lines of study have demonstrated that during early postnatal life, the 
developing brain is particularly susceptible to anesthesia-induced morphological and 
functional alterations that may cause permanent behavioral impairments later in life. However, 
conflicting evidence exists for the long-term effects of early postnatal anesthesia, and the roles 
of the depth, time point of exposure, and total exposure duration in the potential permanent 
effects of anesthesia remain obscure. Moreover, in human studies, the conclusions are limited 
by confounding factors. As anesthesia during adolescence is rarely delivered without 
accompanying surgery, the long-term effects on learning and memory may be influenced by 
the surgery itself or the condition that is being surgically treated. Nevertheless, these 
detrimental effects seem to be specific to certain sensitive temporal windows during early 
development, and therefore highly dependent on the time point of exposure to anesthesia 
(Figure 3).  
 17 
Figure 3. Phases of early brain maturation and the developmental stage-dependent 
impact of anesthesia in rodents (Farhy-Tselnicker & Allen, 2018; Thion & Garel, 2017). The 
impact of anesthesia on the developing brain is dependent on the maturation stage during 
anesthesia exposure. Anesthesia during the first postnatal week in rodents is associated with 
increased neuroapoptosis, whereas anesthesia during the second and third postnatal weeks 
lacks such effects and induces synaptogenesis instead. 
 
2.3.2. Antidepressant effects of anesthesia 
 
Interest in the potential antidepressant effects of general anesthetics emerged during the 1980s 
after the discovery that the postictal electrocerebral silence after ECT may predict the onset of 
action of ECT’s therapeutic effects (Langer et al., 1985). General anesthetics cause a similar 
silencing of EEG power during anesthesia (Campagna et al., 2003; Clark & Rosner, 1973). 
Indeed, early preliminary clinical studies investigating the antidepressant potential of 
isoflurane demonstrated an antidepressant effect of brief, repeated burst-suppressing 
anesthesia in patients (Carl et al., 1988; Engelhardt et al., 1993; Langer et al., 1985, 1995). In 
the first small-scale clinical study by Langer and colleagues (1985), isoflurane anesthesia 
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alleviated depressive symptoms in 9 out of 11 patients. These initial findings were supported 
by studies comparing the effects of repeated burst-suppressing isoflurane anesthesia to ECT 
(Carl et al., 1988; Engelhardt et al., 1993). A follow-up study found six consecutive 15-minute 
burst-suppressing isoflurane anesthesia exposures to elicit a more effective and rapid 
antidepressant response than ECT, accompanied with fewer cognitive side effects (Langer et 
al., 1995). However, many subsequent findings with isoflurane and other volatile anesthetics 
remained inconsistent, and this line of study was inactive for decades (Garcia-Toro et al., 2004; 
García-Toro et al., 2001; Greenberg et al., 1987).  
 
Recently emerging clinical and preclinical observations have restimulated interest in the 
antidepressant potential of deep anesthesia (Tadler & Mickey, 2018). Indeed, brief burst-
suppressing anesthesia induced by isoflurane or propofol has shown promise in small clinical 
trials, echoing the early positive findings (Mickey et al., 2018; Weeks et al., 2013). A series of 
ten 15-minute burst-suppressing isoflurane anesthesia sessions had comparable antidepressant 
efficacy to ECT in patients with medication-refractory depression. They were also more 
tolerable than ECT in terms of neurocognitive side effects (Weeks et al., 2013). In another 
clinical trial, 10 burst-suppressing propofol infusions administered for 15 minutes three times 
per week rapidly alleviated depressive symptoms (Mickey et al., 2018). These findings are 
supported by recent preclinical studies demonstrating that a single burst-suppressing isoflurane 
anesthesia produces antidepressant-like effects in the FST and rodent depression models 
(Antila et al., 2017; Brown et al., 2018a; Zhang et al., 2019). However, further preclinical and 
clinical research into the antidepressant effects of deep anesthesia is clearly needed. 
 
2.4. Rapid-acting antidepressant ketamine 
 
In 2000, Berman et al. demonstrated that ketamine, an anesthetic drug and non-competitive 
antagonist of glutamatergic NMDAR, rapidly alleviated depressive symptoms in a matter of 
hours, even in treatment-resistant patients, after a single subanesthetic administration (Berman 
et al., 2000). This groundbreaking finding was replicated in numerous other double-blind, 
placebo-controlled clinical studies in depressed patients (Murrough et al., 2013; Zarate et al., 
2006a). In addition, ketamine rapidly reduced suicidal ideation in depressed patients 
(Diazgranados et al., 2010; Price et al., 2009; Wilkinson et al., 2018). Ketamine has also shown 
antidepressant efficacy in patients who do not respond to ECT (Ibrahim et al., 2011). The 
antidepressant and anti-suicidal effects of ketamine may be sustained for weeks in some 
individuals but are commonly more transient. The majority of patients who respond to a single 
infusion of ketamine do not meet response criteria two weeks after administration (Pennybaker 
et al., 2017). 
 
Ketamine was initially synthesized in 1962 and developed as an anesthetic drug, obtaining 
approval for clinical use from the FDA in 1970 (Kalmoe et al., 2020). Ketamine was first 
widely used as a battlefield anesthetic in the Vietnam War before gaining widespread use in 
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clinical anesthesiology. Ketamine is structurally similar to the hallucinogenic drug 
phencyclidine (PCP) and belongs to the chemical group of arylcyclohexylamines. It produces 
dose-dependent anesthesia that differs from the anesthesia induced by non-NMDAR binding 
agents, such as volatile anesthetics and propofol, in its dissociative quality. The use of 
ketamine in clinical anesthesia is favored due to its minimal effect on cardiac and respiratory 
functions. 
 
In off-label use for treating depression, racemic ketamine, consisting of (S)- and (R)-
enantiomers, is administered as an intravenous infusion for 40–60 minutes in a subanesthetic 
dose (0.5 mg/kg) (aan het Rot et al., 2012). This dose is generally well tolerated, but the 
adverse effects of ketamine and the short duration of its therapeutic effect limit its widespread 
clinical use (Krystal et al., 2019). Six repeated ketamine infusions have been proven to be safe, 
well tolerated, and feasible in maintaining the antidepressant effects, but the long-term safety 
of ketamine requires further investigation (aan het Rot et al., 2010; Murrough et al., 2013). A 
subanesthetic dose of ketamine may cause dissociative symptoms reminiscent of acute 
psychosis, which include extreme perturbations in thought and sensory processing, 
hallucinations, and euphoria. These psychotomimetic effects also present the risk of 
ketamine’s potential misuse since this state is desired in the recreational use of the drug. 
 
Findings of the antidepressant effects of ketamine are supported by a large body of preclinical 
research demonstrating ketamine’s antidepressant-like effects in a variety of animal models of 
depression, such as learned helplessness and unpredictable CMS (Autry et al., 2011; Li et al., 
2011; Li et al., 2010; Lindholm et al., 2012; Maeng et al., 2008; Zanos et al., 2016). Despite 
extensive preclinical studies, the precise neurobiological mechanisms of ketamine’s 
antidepressant action remain unclear. However, various hypotheses have been proposed, many 
of which partially align with the neurotrophic and network hypotheses of depression 
previously discussed. 
 
2.4.1. Neurobiological basis of ketamine’s antidepressant action 
 
The neurobiological mechanisms underlying the rapid antidepressant effects of subanesthetic 
doses of ketamine are complex and have not been fully elucidated. The mechanisms likely 
exceed mere NMDAR antagonism since other NMDAR antagonists, such as the long-acting 
antagonist memantine, have proven insufficient in producing rapid antidepressant responses 
in clinical trials (Newport et al., 2015; Zarate et al., 2006b). Memantine does have a different 
NMDAR trapping profile than ketamine, but further evidence indicates additional mechanisms 
to be involved in ketamine’s antidepressant action (Kotermanski et al., 2009; Mealing et al., 
1999). Indeed, the clinical effects of ketamine are maintained well beyond the acute 
pharmacological effects of the drug (plasma half-life 2–3 h) and commonly emerge only after 
the psychotomimetic effects of ketamine have subsided (aan het Rot et al., 2012). This 
indicates that other mechanisms beside acute NMDAR antagonism are involved in the 
sustained antidepressant effects. 
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Despite having an antagonizing effect on glutamatergic NMDAR, subanesthetic doses of 
ketamine paradoxically increase cortical excitability (Abdallah et al., 2018a; Cornwell et al., 
2012; Di Lazzaro et al., 2003). This effect is hypothesized to be caused by ketamine 
preferentially inhibiting NMDAR in GABAergic inhibitory interneurons, leading to 
disinhibition and increased firing of glutamatergic pyramidal neurons (Figure 4A) (Abdallah 
et al., 2018b; Homayoun & Moghaddam, 2007). Indeed, subanesthetic doses of ketamine have 
been indicated to acutely increase glutamatergic neurotransmission in non-NMDA 
glutamatergic receptors, particularly in AMPA receptors (AMPAR) (Zanos & Gould, 2018). 
In humans, subanesthetic ketamine infusion caused an increase in prefrontal glutamate release, 
as measured by magnetic resonance spectroscopy-based detection of 13C-labeled glutamine 
(Abdallah et al., 2018a). Extracellular levels of glutamate were shown to increase after 
subanesthetic doses of ketamine (10–30 mg/kg, i.p.) in rat PFC, while the effect was absent at 
higher doses (50 mg/kg, i.p.) (Moghaddam et al., 1997). In contrast, an anesthetic dose of 
ketamine (200 mg/kg, i.p.) caused a decrease in extracellular glutamate levels. AMPAR 
antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) 
blocked the effects of ketamine in the learned helplessness model and FST in mice (Autry et 
al., 2011; Maeng et al., 2008) and in learned helplessness, tail suspension test (Koike et al., 
2011), and FST in rats (Koike & Chaki, 2014). The disinhibition hypothesis is also supported 
by a recent electrophysiological study, where a low dose of ketamine reduced inhibitory input 
to CA1 pyramidal cells in rat hippocampal slices (Widman & McMahon, 2018). Furthermore, 
subanesthetic ketamine was found to increase calcium transients in cortical pyramidal neurons, 
as measured by two-photon imaging of head-fixed mice (Ali et al., 2020). In addition to 
selective action on interneuron NMDARs, ketamine has been proposed to directly block NR2B 
subunit-containing extrasynaptic NMDARs in pyramidal neurons that are tonically activated 
by ambient glutamate under basal conditions (Figure 4B) (Miller et al., 2016). This blockade 
is proposed to increase excitatory drive by disinhibiting protein synthesis. 
 
Similarly to its relationship with monoaminergic antidepressants, BDNF has been indicated in 
the antidepressant-like behavioral effects of ketamine. The antidepressant effects of 
subanesthetic ketamine (3–10 mg/kg, i.p.) in FST were blocked by inducible knockout of 
BDNF in mouse forebrain areas (Autry et al., 2011) and in BDNFVal66Met knock-in mice (Liu et 
al., 2012). A postnatal conditional knockout of TrkB also negated ketamine’s behavioral 
effects (Autry et al., 2011). Furthermore, the same study demonstrated that ketamine and 
another NMDAR antagonist MK-801 (0.1 mg/kg, i.p.) increased BDNF protein expression in 
the cortex only 30 minutes after administration, but the effect remained transient and was not 
observed after 24 hours. An infusion of function-blocking BDNF antibody in the rat medial 
PFC also blocked the antidepressant-like effects of subanesthetic ketamine (10 mg/kg, i.p.) in 
FST, suggesting that BDNF release is necessary for ketamine’s antidepressant action (Lepack 
et al., 2014). The same study found that calcium channel antagonists verapamil and nifedipine 
neutralized ketamine’s effects in FST, indicating a role for L-type voltage-dependent calcium 
channel activation as well. However, another study reported a higher range subanesthetic dose 
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of ketamine (50 mg/kg, i.p.) to retain its antidepressant-like effects in FST in heterozygous 
Bdnf+/- mice (Lindholm et al., 2012). 
 
Ketamine has also been shown to recruit molecular machinery connected to neurotrophic 
function. Subanesthetic ketamine (10 mg/kg, i.p.) rapidly induced phosphorylation of mTOR 
and subsequently increased synaptic protein expression and formation of excitatory synapses 
in the mouse PFC (Li et al., 2010). Indeed, ketamine also dose-dependently increased 
phosphorylation of other signaling proteins indicated in BDNF signaling and synapse 
formation, including 4E-BP1, p70S6K, MAPK, and AKT. However, these signaling effects 
were transient and had reduced back to baseline levels two hours after ketamine delivery. The 
signaling effects were dependent on AMPAR and mTOR activation since pretreatment with 
AMPAR antagonist NBQX or mTOR antagonist rapamycin completely abolished the 
behavioral and molecular effects of ketamine. After the molecular signaling effects subsided, 
an increase in the expression of synaptic proteins, including postsynaptic density protein 95 
(PSD95), activity-regulated cytoskeleton-associated protein (Arc), synapsin I, and GluR1 was 
observed. Furthermore, two-photon imaging revealed increased spine density in the apical tuft 
pyramidal neurons in the medial PFC. Similar mTOR-dependent behavioral and signaling 
effects were observed with an NMDAR subunit NR2B-specific antagonist, Ro 25-6981. 
Studies aiming to replicate the findings have, however, been inconsistent, and the role of 
mTOR pathway in ketamine’s antidepressant effect remains debated (Autry et al., 2011; Zanos 
et al., 2016). Ketamine was also shown to rescue cortical spine loss induced by chronic 
exposure to corticosterone in the drinking water of mice (Moda-Sava et al., 2019). 
Interestingly, the effects were selective to spines lost as a result of the corticosterone treatment. 
However, a majority of spines lost during corticosterone treatment still remained unrestored 
after ketamine treatment. 
 
The transcriptional and translational regulation of neurons has been consistently shown to be 
influenced by ketamine. Subanesthetic ketamine (3 mg/kg, i.p.) and MK-801 (0.1 mg/kg, i.p.) 
rapidly inactivated the phosphorylated form of eukaryotic elongation factor 2 (eEF2), a 
suppressor of dendritic translation, enabling rapid translation of BDNF transcripts in the mouse 
HC (Autry et al., 2011). The authors proposed that this inactivation was mediated by 
ketamine’s ability to inhibit spontaneous NMDAR-dependent excitatory postsynaptic currents 
(Figure 4C). Inhibition of the translational control of eEF2 with antagonists rottlerin and 
NH125 was found to be sufficient to elicit an antidepressant-like behavioral response in FST. 
Ketamine (15 mg/kg, i.p.) also activated transcription factor CREB in the rat PFC (Réus et al., 
2016). Another cell signaling component shown to have significance in ketamine’s 
antidepressant response is glycogen synthase kinase 3 (GSK3), a protein kinase that is 
expressed in α and β isoforms and whose function is regulated by BDNF through the PI3K 
signaling pathway (Li & Jope, 2010). GSK3 inhibits the function of transcription factor CREB 
and is highly active at rest, but phosphorylation of its serine-9 residue inactivates it, 
disinhibiting CREB. GSK3 has been previously implicated in the mood-stabilizing effect of 
lithium (Stambolic et al., 1996). A subanesthetic dose of ketamine (10 mg/kg, i.p.) inhibited 
 22 
GSK3 30 and 60 minutes after administration in mouse PFC and HC (Beurel et al., 2011). In 
the same study, a knock-in mutation of GSK3 negated the antidepressant-like effects in the 
learned helplessness model.  
 
It has been recently proposed that ketamine exerts its antidepressant effect through the 
influence of its hydroxynorketamine (HNK) metabolite (2R,6R)-HNK (Zanos et al., 2016). In 
vivo, racemic ketamine is rapidly metabolized to several stereoisomers of HNK and 
norketamine. A 10 mg/kg (i.p.) administration of (2R,6R)-HNK exerted an antidepressant-like 
response in mouse FST and learned helplessness. However, a modified form of ketamine, 
deuterated in the C6-position so that its metabolism to HNK is hindered while its 
pharmacological properties are maintained, lacked any antidepressant-like effects. The 
behavioral effects of (2R,6R)-HNK were also blocked by a pretreatment with NBQX, 
demonstrating the effects to be dependent on AMPAR activation. Moreover, (2R,6R)-HNK 
lacked ketamine-related drug-seeking behavior and side effects, such as deficits in prepulse 
inhibition and locomotor coordination in rotarod test. Further studies indicated (2R,6R)-HNK 
to elicit an antidepressant-like response through negative modulation of presynaptic 
metabotropic glutamate receptor 2 (mGluR2) autoreceptors that under basal conditions inhibit 
presynaptic glutamate release (Figure 4D) (Zanos et al., 2019). Other studies, however, found 
no effects of HNK on depressive-like behavior in mice subjected to lipopolysaccharide 
injections or chronic social defeat stress (Yamaguchi et al., 2018; Yang et al., 2017) or in rats 
subjected to learned helplessness (Shirayama & Hashimoto, 2018). Furthermore, small-scale 
clinical studies have found an inverse correlation between plasma HNK concentration and 
antidepressant response after ketamine infusions (Farmer et al., 2020; Grunebaum et al., 2019). 
Therefore, the role of HNK in ketamine’s antidepressant effects remains controversial.  
 
In addition to NMDARs, ketamine targets several other receptors and neurotransmitter systems 
in the brain, some of which may contribute to its antidepressant effects. For instance, a 
potential role for the opioid system in ketamine’s action has been indicated since pretreatment 
with opioid receptor antagonist naltrexone negated ketamine’s antidepressant effect in a small-
scale clinical study (Williams et al., 2018). In addition, ketamine’s antidepressant-like effects 
in FST were abolished by the dopaminergic D2/D3 receptor antagonist haloperidol, and by 
central depletion of serotonin, indicating a role for monoaminergic systems as well (Gigliucci 
et al., 2013; Li et al., 2015). Other identified targets of ketamine include, among others, 
muscarinic and nicotinic acetylcholine receptors and voltage-gated ion channels, as reviewed 









Table 1. Identified receptor targets of (R, S)-ketamine. HCN1 = hyperpolarization-




Overall, various hypotheses have been proposed to underlie ketamine’s antidepressant effects, 
but shared components of the proposals include increased glutamatergic tone and AMPAR-
dependent regulation of neurotrophic signaling and a subsequent synthesis of synaptic proteins 
that leads to alterations in synaptic plasticity (Figure 4). Further insight into the precise 
antidepressant mechanisms of ketamine may be gained by considering the similar effects that 






Muscarinic Acetylcholine receptor Antagonist
Nicotinic Acetylcholine receptor Antagonist





μ opioid receptor Agonist
κ opioid receptor Agonist
δ opioid receptor Agonist
Voltage-gated sodium channel Antagonist
L-type Voltage-dependent calcium channel Antagonist
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Figure 4. Proposed cellular mechanisms of ketamine’s antidepressant action. Suggested 
mechanisms of ketamine include A) disinhibition of pyramidal neurons through selective 
blockade of NMDARs in GABAergic interneurons, B) blockade of extrasynaptic NMDARs 
that disinhibits mTOR activity, C) blockade of spontaneous NMDAR activation that 
dephosphorylates eEF2, allowing for rapid translation of BDNF, D) disinhibition of 
presynaptic glutamate release through blockade of mGluR2 by HNK. Different proposals 
converge on BDNF-dependent upregulation of synaptic protein synthesis and increased 
synaptogenesis. Figure modified after Zanos & Gould (2018). 
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2.5. Shared mechanisms of rapid-acting treatment options 
 
Despite the increasing enthusiasm for the antidepressant effects of ketamine, it is by no means 
the first treatment option that has demonstrated rapid antidepressant effects. Indeed, ECT has 
long been the treatment of choice when classical antidepressants have failed to produce 
treatment response or a more rapid alleviation of symptoms is critical due to acute suicidality 
(Payne & Prudic, 2009). Interestingly, sleep deprivation has also consistently shown to rapidly 
alleviate depressive symptoms in patients, although the effect is usually short-lived (Giedke & 
Schwärzler, 2002; Wu & Bunney, 1990). Moreover, a variety of pharmacological agents 
demonstrating rapid antidepressant efficacy have emerged. Many of these are anesthetics, but 
classical psychedelics, such as psilocybin, have also gained recent research interest (Carhart-
Harris & Goodwin, 2017). All of these treatments modulate cortical excitation-inhibition 
balance and neuronal excitability, but neurotrophic mechanisms have also been implicated, 
indicating that parallel neurobiological processes may underlie the antidepressant effects of 
these diverse rapid-acting treatment approaches. 
 
ECT was first introduced in the treatment of psychiatric disorders in the 1930s (Payne & 
Prudic, 2009). Despite decades of drug development, ECT remains among the most effective 
antidepressant treatments in clinical use (Pagnin et al., 2004). It is generally considered to be 
a “last resort” treatment, when the patient has failed to respond to several conventional 
antidepressant treatments, or under clinical urgency, when the patient is expressing 
hallucinations or delusions, catatonia, or suicidality (Payne & Prudic, 2009). Other indications 
of ECT include schizophrenia, catatonia, and manic bipolar states (Kellner et al., 2012). In 
ECT, a brief pulse of electrical current is delivered to the anesthetized patient’s scalp, leading 
to transient epileptiform activity in the EEG. This treatment can efficiently and rapidly 
alleviate depressive symptoms even when conventional antidepressants have failed to do so 
(Abbott et al., 2014; Pagnin et al., 2004; UK ECT Review Group, 2003). Typically, repeated 
stimulations are required to achieve therapeutic remission, but the response to ECT usually 
emerges faster than the response to prescription antidepressants (Pagnin et al., 2004). There 
are currently no clearly identified clinical predictors for ECT response. However, recent meta-
analyses have found ECT to be particularly effective in elderly people and patients with 
psychotic symptoms, short depressive episodes, or no previous medication failures (Haq et al., 
2015; Van Diermen et al., 2018). In addition, a specific gene promoter methylation of p11 has 
been proposed as a biomarker to predict ECT treatment response (Neyazi et al., 2018).  
 
Despite a negative impression of ECT among general public, fueled, among other things, by 
its inaccurate depiction in popular culture, modern ECT involves oxygenation, general 
anesthesia with neuromuscular blockade, and physiological monitoring, making it a relatively 
safe treatment option (Husain et al., 2004). Adverse effects of ECT include transient 
anterograde amnesia, head and muscle ache, and nausea, but these effects often pass within 
hours of treatment (Lisanby, 2007). A rarer but persistent adverse effect is retrograde amnesia, 
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which commonly involves poor recollection of events directly before ECT administration but 
sometimes includes amnesia for events dating months or even years before ECT. 
 
Neurobiological mechanisms underlying the antidepressant action of ECT remain poorly 
understood, but various proposals have suggested seizure activity, anticonvulsant effects, and 
neurotrophic function to be involved (Abbott et al., 2014). The importance of seizure activity 
was established in the 1960s, when pretreatment with an anticonvulsant drug, lidocaine, was 
found to abolish the antidepressant effects of ECT (Cronholm & Ottosson, 1960). The 
intriguing ability of seizures to rapidly alleviate depressive symptoms is further supported by 
findings regarding a volatile convulsant, flurothyl (hexafluorodiethyl ether) (Fink, 2014). A 
seizure induced by flurothyl inhalation was found to be equally efficient to ECT in the 
treatment of depression but with lower incidence of cognitive side effects (Small et al., 1968). 
However, it has been acknowledged that generalized seizures per se do not reliably produce 
antidepressant effects, indicating that other factors must be involved in the antidepressant 
effects of ECT (Perera et al., 2004). The anticonvulsant hypothesis is based on observations 
indicating that the ECT-induced increase in seizure threshold correlates with the treatment’s 
antidepressant response (Sackeim, 1999). Localization of the stimulus and delivered electrical 
dosage have also been shown to play a role, since remission rates and cognitive side effects of 
ECT have been demonstrated to depend on the electrode placement and stimulus intensity 
(Lisanby, 2007; Nobler et al., 1993; Sackeim et al., 2000). 
 
ECT has been shown to influence a variety of brain functions, including monoaminergic, 
GABAergic, and glutamatergic neurotransmission, neuroendocrine function, and neurotrophic 
signaling (Kellner et al., 2012). The neurotrophic effects in particular are reminiscent of those 
induced by ketamine and other antidepressants. In depressed human patients, plasma BDNF 
levels normalized to the levels of healthy controls after ECT (Piccinni et al., 2009). This effect 
correlated with treatment response since non-responders demonstrated a more modest increase 
in plasma BDNF levels. Repeated electroconvulsive seizures (ECS, an animal model of ECT) 
influenced neurotrophic action in the brain by increasing the expression of BDNF mRNA 
(Altar et al., 2004; Nibuya et al., 1995; Smith et al., 1997; Zetterström et al., 1998) and protein 
(Altar et al., 2003; Angelucci et al., 2002) in the rat PFC and HC. ECS in rodents has also been 
shown to upregulate various molecular markers connected to neuronal excitation. It acutely 
upregulated several activity-dependent immediate-early genes (IEGs), including Arc, c-fos and 
Egr1 in hippocampal and cortical regions in rodents (Dyrvig et al., 2014; Larsen et al., 2005). 
IEGs play a significant role in the genomic response to stimulus as their products include 
transcription factors and effector proteins that are involved in synaptic modifications and 
plasticity (Dyrvig et al., 2014). In addition, a single ECS caused a robust upregulation of 
MAPK phosphorylation in the rat PFC (Hansen et al., 2007). Unexpectedly, ECS acutely 
decreased TrkB phosphorylation. 
 
Increased neurogenesis and synaptogenesis have also been implicated in ECT’s antidepressant 
actions. ECS increased neurogenesis in the rat dentate gyrus (Madsen et al., 2000) and cell 
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proliferation in the frontal cortex (Madsen et al., 2005). Another study found repeated ECS 
treatments to increase hippocampal volume and the number of hippocampal neurons and spine 
synapses (Chen et al., 2009). Similar observations have also been made in non-human 
primates, where three ECS administrations per week for four weeks induced cell proliferation 
and neurogenesis in the male bonnet monkey dentate gyrus (Perera et al., 2007). The effects 
were observed immediately after the treatment course and were sustained at four weeks after 
the interventions. 
 
EEG has been widely used as a research tool for ECT since its entry into the clinical domain 
(Nobler et al., 1993; Sackeim, 1999). Initially, seizure duration was believed to predict the 
antidepressant efficacy of ECT, but this hypothesis was later discarded. More recently, the 
search for predictive treatment efficacy markers of ECT has been focused on longitudinal EEG 
signature during and after treatment. In particular, the antidepressant efficacy of ECT has been 
linked to postictal suppression of cortical EEG activity (Nobler et al., 1993; Sackeim et al., 
1996; Suppes et al., 1996). This electrocerebral silence emerged soon after the seizure and was 
associated with a widespread decrease in cerebral blood flow (Nobler et al., 1994) and 
metabolism (Nobler et al., 2001). Increased postictal delta EEG power (1–4 Hz) was associated 
with a positive treatment response at 2-month follow-up monitoring (Sackeim et al., 1996). No 
notable postictal slowing was observed with ineffective low intensity right unilateral ECT 
(Sackeim et al., 2000). This determinant of treatment outcome also encouraged the initial 
studies examining the antidepressant effects of isoflurane anesthesia since it produced a similar 
slowing of cortical EEG activity (Langer et al., 1985, 1995). 
 
Indeed, deep isoflurane anesthesia also rapidly regulated molecular alterations intimately 
associated with the therapeutic effects of ketamine, namely TrkB signaling (Antila et al., 
2017). The effects of isoflurane on TrkB were dose-dependent, and the most prominent effects 
were seen with a dosing regimen leading to a burst-suppressing EEG pattern (Theilmann et al., 
2019). Notably, isoflurane regulated TrkB signaling far more readily than ECS (Antila et al., 
2017; Hansen et al., 2007). A brief exposure to isoflurane anesthesia produced antidepressant-
like behavioral responses in the rat learned helplessness model of depression (Brown et al., 
2018a). Interestingly, the same study found another anesthetic compound, halothane, which 
lacks the capability to produce isoelectric EEG and burst-suppression, to bring no such effects 
although it readily regulates TrkB signaling (Antila et al., 2017; Brown et al., 2018a).  
 
Another anesthetic that has demonstrated antidepressant potential is nitrous oxide (N2O), 
commonly referred to as “laughing gas.” N2O is a colorless and odorless gas with over 150 
years of history in clinical use (Sanders et al., 2008). Like ketamine, the main pharmacological 
function of N2O is NMDAR antagonism. N2O is primarily used in clinical anesthesia and 
analgesia in labor and delivery, and dentistry. It is one of the least potent anesthetics, with a 
minimum alveolar concentration (MAC: alveolar concentration of inhaled anesthetic that 
prevents motor response in 50% of patients in response to surgical incision) of 104%, whereas 
isoflurane, for instance, has a MAC value of 1.17% (Mapleson, 1996). This means that N2O 
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by itself is insufficient in producing surgical anesthesia since, to avoid hypoxia, it can be 
administered only at a maximum concentration of 70% (Nagele et al., 2018). It is therefore 
mainly used as an adjunct agent in combination with other anesthetics. N2O has a notably rapid 
onset and offset of action, and it does not undergo significant metabolism. In a recent clinical 
study, N2O demonstrated rapid antidepressant efficacy in treatment-resistant patients (Nagele 
et al., 2015). Similarly to the effects of ketamine, the antidepressant effects of N2O were most 
pronounced 24 hours after the treatment and lasted up to a week in some patients. However, 
N2O also demonstrates misuse potential, reported as long ago as the Victorian era, since it is 
recreationally used to achieve brief euphoric intoxication as inhalations from whipped cream 
containers (van Amsterdam et al., 2015). Studies examining the neurobiological effects of N2O 
in an antidepressant context have so far remained scarce. 
 
In addition to ECT, sleep deprivation provides a non-pharmacological means to alleviate 
depressive symptoms. Sleep deprivation for 24–48 hours has been robustly shown to relieve 
depression in a subset of patients (Wu & Bunney, 1990). The effects, however, remain 
transient, and a depressive relapse commonly occurs after a subsequent sleep period (Wiegand 
et al., 1993; Wu & Bunney, 1990). However, for some patients, the improvement of symptoms 
can last up to weeks (Giedke & Schwärzler, 2002). These findings are supported by animal 
studies demonstrating increased swimming behavior of rats in FST after 24 hours of sleep 
deprivation (Lopez-Rodriguez et al., 2004). Interestingly, sleep deprivation also shares several 
molecular effects with other rapid-acting antidepressant treatments. Total and partial sleep 
deprivation for one night has been reported to rapidly elevate plasma BDNF levels for the 
following day in depressed patients (Giese et al., 2014; Gorgulu & Caliyurt, 2009). Moreover, 
the increase in plasma BDNF levels was found to correlate with the antidepressant treatment 
response (Gorgulu & Caliyurt, 2009). Another study found a 24-hour sleep deprivation in 
naïve rats to increase Bdnf mRNA levels, particularly in hippocampal regions (Conti et al., 
2007). Sleep deprivation also upregulates IEG c-fos in several areas of the rat brain (Cirelli et 
al., 1995). Functional neuroimaging studies have shown sleep deprivation responders to 
express increased metabolic activity in the medial PFC and ventral anterior cingulate cortex 
(Wu et al., 2001, 2008). To our knowledge, the effects of sleep deprivation on TrkB signaling 
have not been investigated. 
 
Another putative class of compounds that has demonstrated rapid antidepressant effects is 
classical psychedelics, which includes psilocybin and lysergic acid diethylamide (LSD) 
(Carhart-Harris & Goodwin, 2017). Classical psychedelics have a pharmacological 
mechanism distinct from that of anesthetics in that they primarily function as agonists in 
serotonergic 5-HT2A receptors (Nichols, 2016). After decades of hiatus in the clinical research 
of psychedelics, recent findings have revitalized interest in the study of their potential for 
treating mood disorders. In a preliminary clinical trial, a single dose of psilocybin 
demonstrated rapid antidepressant effects that were sustained even 3 months after the treatment 
(Carhart-Harris et al., 2016). In vitro, LSD and other serotonergic psychedelics have been 
demonstrated to increase dendritic spine density and induce synaptogenesis similarly to 
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ketamine (Ly et al., 2018). These effects were blocked by TrkB inhibitor ANA-12, indicating 
that these effects are mediated by TrkB activation. However, these neurotrophic effects have 
yet to be investigated in vivo.  
 
In conclusion, multiple complex mechanisms appear to be involved in a rapid-acting 
antidepressant response, but alterations in cortical excitation and neurotrophic action and the 
subsequent recruitment of cellular machinery that leads to morphological and functional 
synaptic plasticity has been implicated in nearly every effective antidepressant treatment. 
However, these findings have not yet translated to clinical breakthroughs, indicating 































3. Aims of the study 
 
Anesthetics profoundly impact neuronal function during different stages of development, and 
they have garnered academic interest in the treatment of MDD. Burst-suppressing anesthesia 
and subanesthetic ketamine, in particular, have been shown to rapidly alleviate depressive 
symptoms in adults, but the underlying neurobiological mechanisms remain debated. 
Moreover, the clinical results of burst-suppressing anesthesia have so far been inconsistent. 
Despite having a pharmacological target clearly distinct from that of ketamine, isoflurane was 
recently shown to induce neurotrophic signaling, a key mechanism implied in the rapid 
antidepressant effects of ketamine (Antila et al., 2017). The main objectives of this thesis are 
to further elucidate the behavioral effects of isoflurane in rodents with two approaches—by 
determining the potential adverse effects of early-life anesthesia and testing its efficacy in a 
rodent model of depression—and to investigate how different antidepressant anesthetics 
regulate molecular and electrophysiological events associated with the rapid antidepressant 
effects of ketamine.  
 
The specific aims of the subprojects in this thesis were as follows. 
 
I Investigate the long-term behavioral consequences of repeated brief isoflurane 
anesthesia when delivered during early postnatal development in male mice (I). 
II Investigate the antidepressant effects of deep burst-suppressing isoflurane anesthesia 
in a rat chronic mild stress model of depression (II). 
III Investigate the shared neurobiological effects evoked by rapid-acting antidepressants 
ketamine, nitrous oxide, and flurothyl in adult mice (III, IV) by: 
conducting pharmaco-EEG studies in freely-moving adult mice 
studying time-dependent effects on key molecular determinants associated with rapid 
antidepressant effects 
studying dose- and time-dependent effects of ketamine (and its hydroxynorketamine 













4. Materials and methods 
 
The main methods used in this thesis are briefly outlined here. The details of the methods and 
specifications of the chemicals and consumables used are described in corresponding research 




Studies I, III, and IV were conducted using C57BL/6JRccHsd mice (Harlan 
Laboratories/Envigo, Venray, The Netherlands). Animals were maintained in standard 
conditions (21 °C, 12-h light-dark cycle) in the facilities of the University of Helsinki with ad 
libitum access to food and water.  
 
In study II, we used a Crl:WI(Han) substrain of Wistar outbred rats (Charles River 
Laboratories, Wilmington, Massachusetts, USA) since this strain was previously shown to be 
particularly prone to attaining a depressive-like phenotype in response to CMS (Theilmann et 
al., 2016). 
 
All the animal experiments were carried out according to the guidelines of the Society for 
Neuroscience and were approved by the relevant national authorities. 
 
4.2. Behavioral analysis 
 
In study I, to achieve a wide phenotypic characterization of adult mice, the animals were 
exposed to a battery of behavioral tests that included home-cage activity measurement, 
evaluation of nesting behavior, saccharin preference test, measurement of stress-induced 
hyperthermia, light-dark box test, open field test, prepulse inhibition test, Morris water maze 
test, and FST. 
 
In study II, anhedonic-like and anxious behavior was measured by sucrose consumption test, 
open field test, and EPM test. Sucrose consumption test is a canonical method of measuring 
hedonic deficits in rodents (Willner et al., 1987). Animals had access to 1% sucrose solution 
in addition to normal drinking water, and their overnight consumption of sucrose solution was 
measured. 
 
In study III, a well-established learned helplessness model was used to model depressive-like 
behavior. In learned helplessness, the rodent is exposed to inescapable foot shocks (Seligman 
et al., 1975). When later placed in a chamber where escape from the shocks is possible, an 
animal with learned helplessness fails to escape, whereas an unstressed animal would. Learned 
helplessness behavior is alleviated by several antidepressant drugs. 
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4.3. Chronic mild stress 
 
In rodents, CMS is a widely accepted model of depression since it recapitulates a set of 
depressive-like symptoms, such as anhedonia. In rodents, a decreased preference for the 
consumption of sweet solution is considered anhedonic behavior (Willner et al., 1987). In 
study II, we used a stress-sensitive substrain of rats (Crl:WI[Han]) previously shown to 
respond to ECS but not the SSRI drug citalopram (Neyazi et al., 2018). We used a CMS 
protocol that was derived from the protocol described by Willner et al. (1987). Briefly, the 
animals were exposed to one randomized mild stressor every day for three weeks. The stressors 
included swimming in cold (15°C) or hot (40°C) water for 5 or 10 minutes, respectively, wet 
bedding for 16 hours, food deprivation for 24 hours, water deprivation for 14–21 hours, 
restraint stress for 30–60 minutes, and continuous light for 36 hours. 
 
4.4. Sample collection and preparation 
 
In studies II–IV, brain samples for the biochemical analyses were collected at time points 
indicated in the research articles. Briefly, animals were euthanized by cervical dislocation, 
decapitated, and the brain was rapidly collected and submerged in ice-cold phosphate-buffered 
saline. Bilateral PFC and HC samples were manually dissected on a cold plate, snap frozen on 
dry ice, and stored at -80°C until further processing. For total protein extractions, the brain 
samples were homogenized in ice-cold lysis buffer. The samples were centrifuged, and the 
resulting supernatant was collected for further analysis. For quantitative polymerase chain 
reaction (qPCR), total ribonucleic acid (RNA) was extracted from the samples by 
homogenization in Trizol reagent (ThermoScientific). RNA was then phase separated by 
incubating the homogenized samples in chloroform. The aquatic phase containing the RNA 
was collected, and the RNA was precipitated with isopropanol, washed twice with 75% 
ethanol, and dissolved in nuclease-free water.  
 
4.5. Biochemical analysis of samples (Western blot, PCR, 
ELISA) 
 
Changes in protein phosphorylation were assayed by Western blotting as described (Kohtala 
et al., 2016). Briefly, homogenized PFC sample lysates were heated in Laemmli buffer at 
+100°C for 3 minutes, separated in SDS-PAGE under reducing conditions, and blotted on a 
PVDF membrane. Membranes were incubated overnight with the antibodies reported in the 
original research articles, followed by washes with tris-buffered saline with 0.1% Tween 20 
and a 1-hour incubation with horseradish peroxidase-conjugated secondary antibody (1:10 000 
in non-fat dry milk). After subsequent washes, the membranes were visualized by enhanced 
chemiluminescence (ECL Plus, ThermoScientific) and detected with a Biorad ChemiDoc MP 




For qPCR, the RNA extracts were treated with DNAse to digest residual DNA, and the mRNA 
was subsequently reverse transcribed to complimentary DNA (cDNA) with oligo (dT) primer 
and SuperScript III Reverse Transcriptase Mix (ThermoScientific). Real-time qPCR was used 
to quantify the cDNA expression in the reverse-transcribed PFC samples. Briefly, specific 
cDNA regions were amplified using the primers reported in the original articles. Amplification 
reactions were run in LightCycler 480 (Roche) in the presence of SYBR Green reagent 
(ThermoScientific). 
 
In study II, BDNF protein levels were detected via BDNF-specific enzyme-linked 
immunosorbent assay (ELISA). The protein extracts were acidified to pH 3 by 1 M HCl, 
incubated for 15 minutes, and neutralized with 1 M NaOH. The samples were loaded onto a 
96-well, pre-coated with monoclonal BDNF antibody, pre-blocked with bovine serum 
albumin, and incubated for 2 hours. HRP-conjugated secondary monoclonal BDNF antibody 
was added on the plate and, after a subsequent 1-hour incubation and washes, incubated with 
color reagents (hydrogen peroxide and chromogen) for 30 minutes. The reaction was stopped 




In studies III and IV, EEG was recorded via screws surgically placed above the fronto-parietal 
cortex of the mice. Electromyograph (EMG) was also recorded from silver wires placed in the 
nuchal muscles to monitor the vigilance state of the rodents. During the surgery, animals were 
anesthetized with isoflurane (3% induction, 1.5–2% maintenance). Lidocaine (10%) was used 
for local anesthesia and buprenorphine (0.1 mg/kg, s.c.) for post-operative care. All EEG 
recordings and data processing were performed using Spike2 software (version 8.07, 
















5.1. Long-term behavioral effects of repeated isoflurane 
anesthesia during early development (I) 
 
Anesthesia during early brain development has been associated with neuropathological 
changes in rodents, including neuroapoptosis, synapse loss, and persistent behavioral 
abnormalities (Briner et al., 2010; Jevtovic-Todorovic et al., 2003). However, the role of the 
depth, duration, and developmental time point of exposure to anesthesia remains unclear. We 
exposed mouse pups to three brief sessions of isoflurane anesthesia (4% induction, 2% 
maintenance, 30 min) for three consecutive days in two cohorts: at either postnatal days (P)7–
9 or P15–17 (Figure 5). These two time points were selected because earlier studies have 
shown anesthetics to have different effects on the developing brain at these points. While 
anesthesia exposure at P7–9 has been consistently associated with apoptotic neurodegeneration 
(Jevtovic-Todorovic et al., 2003; Tagawa et al., 2014), a later administration at P16 has been 
shown to increase dendritic spine density (Briner et al., 2010; De Roo et al., 2009). Our aim 
was to determine whether these differential neurobiological effects would be reflected in 
different behavioral outcomes in adult animals. Since the pups had to be separated from their 
dams for the duration of anesthesia, another group of animals from both cohorts were subjected 
to maternal separations (MS) of similar duration to control the potential detrimental effects of 
MS. The animals were weaned at P21, and, beginning from postnatal week 9, the mouse 
phenotype was evaluated using a battery of behavioral tests that assess learning and memory, 




Figure 5. Experimental timeline. Abbreviations: P = postnatal day; W = postnatal week. 
Figure reprinted and modified from publication I. 
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When isoflurane anesthesia was delivered at P7–9, the treatments caused no gross phenotypic 
alterations in adult behavior. Animals subjected to anesthesia demonstrated only subtle deficits 
in spatial learning and memory in the Morris water maze test (Figure 6). However, similar 
deficits were also present in the maternal separation group; thus, the effects cannot be 




Figure 6. Early-life exposure to three consecutive and brief sessions of isoflurane 
anesthesia or maternal separations at postnatal days 7–9 bring mild deficit in spatial 
navigation memory. Latency to escape (find the platform) (A, E) and time spent near the 
vicinity of pre-existing platform (quadrant, zone) (B, F) during the first learning trials and 
probe test, respectively. Latency to escape (find the platform) (C, G) and time spent near the 
vicinity of pre-existing platform (quadrant, zone) (D, H) during the reverse learning trials and 
probe test, respectively. Abbreviations: ISO = isoflurane; MS = maternal separation. Data are 
presented as mean ± SEM. *< 0.05, **< 0.01, two-way ANOVA followed by Newman-Keuls 




In the P15–17 cohort, the most pronounced behavioral change was observed in the home cage 
motor activity monitoring. Curiously, isoflurane and maternal separation produced contrasting 
differences in the general locomotor activity of adult animals, with isoflurane-treated animals 
showing hyperactive behavior in relation to non-treated animals, and the MS group showing 
decreased locomotor activity (Figure 7). These effects were particularly pronounced during 
the active period (dark phase) of the animals. 
 
Figure 7. Animals exposed to repeated brief isoflurane anesthesia or maternal 
separation at postnatal days 15–17 show varying circadian activity at adult age. Hourly 
average circadian activity during 7-day monitoring and average circadian activity during 
different light-cycles. Lights off (active period; gray) during 6:00 PM–6:00 AM. 
Abbreviations: ISO = isoflurane; MS = maternal separation. Data are presented as mean ± 
SEM. ***< 0.001 two-way ANOVA followed by Newman-Keuls post hoc test MS vs. Sham. 
###< 0.001, ##< 0.01 two-way ANOVA followed by Newman-Keuls post hoc test ISO vs. 
MS. Figure reprinted and modified from publication I. 
 
Overall, our study indicates that repeated brief exposure to isoflurane anesthesia during early 
postnatal development in mice produces differential, yet relatively modest behavioral 
alterations in adulthood, that depend on the developmental time point of administration. 
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5.2. Lack of behavioral effects of isoflurane anesthesia in the rat 
CMS model (II) 
 
Postictal slowing of EEG activity has been proposed to predict the onset of action of the 
antidepressant effects of ECT (Nobler et al., 1993; Sackeim et al., 1996; Suppes et al., 1996). 
Isoflurane has a capability to produce electrocerebral silence similar to that of ECT during 
anesthesia but without the preceding convulsions and seizure activity. Indeed, repeated 
isoflurane anesthesia has demonstrated intriguing antidepressant potential in preliminary 
clinical studies (Langer et al., 1985, 1995; Weeks et al., 2013). Moreover, only a single, brief 
isoflurane anesthesia has demonstrated antidepressant-like effects in the FST, learned 
helplessness model, and CMS model in mice (Antila et al., 2017; Brown et al., 2018a; Zhang 
et al., 2019). To test this “cerebral silence” hypothesis and further elucidate the antidepressant 
potential of isoflurane, we used the CMS model in a substrain of rats that have been previously 
shown to respond to ECS but not to the SSRI antidepressant citalopram (Neyazi et al., 2018). 
 
After 3 weeks of CMS exposure, the stress-exposed rats were divided into stress-resilient and 
anhedonic groups, based on the individual rats’ response to stress in the sucrose consumption 
test. Rats whose sucrose consumption showed a >25% within-subject decrease were 
considered anhedonic (14 out of 26 stressed animals), while those that showed <10% decrease 
in sucrose consumption were considered stress-resilient (12 out of 26 animals). After the stress 
exposure, animals were exposed to repeated sessions of isoflurane anesthesia (4% induction 
for 2 minutes, 2% maintenance for 13 minutes) or sham treatments in an anesthesia chamber 
(room air, 15 minutes) for a total of five times, once every three days. Anhedonic-like and 
anxious behavior was measured after the first, third, and fifth treatments in a sucrose 
consumption test and open field test, and after the fifth treatment in an EPM test (Figure 8). 
 
 
Figure 8. Experimental timeline. CMS = chronic mild stress; EPM = elevated plus-maze; 
ISO = isoflurane; OFT = open field test; SCT = sucrose consumption test. Figure reprinted 
from publication II. 
 
Somewhat unexpectedly, isoflurane had essentially no impact on the behavior of the stressed 
rats at any point during the course of experiments (Figure 9). It is unlikely that this lack of 
isoflurane effect is due to insufficient “EEG silencing” since the employed dosing generates 
noticeably reproducible EEG burst-suppression (Leikas et al., 2017; Theilmann et al., 2019).  
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Figure 9. Repeated isoflurane exposure caused no notable behavioral alterations in any 
of the treatment groups. (A) Changes in sucrose consumption in different treatment groups 
over the course of three weeks. (B) Distance moved and duration spent at the center of the 
arena in open field test after the 5th isoflurane exposure. (C) Effects of repeated exposure to 
isoflurane anesthesia in elevated plus maze test. Data are presented as mean ± SEM. *< 0.05, 
two-way ANOVA followed by Sidak’s multiple comparisons test. Figure reprinted from 
publication II. 
 
Another goal of our study was to examine whether the depressive-like phenotype after CMS 
would be reflected in cortical and hippocampal BDNF expression and whether the treatment 
with isoflurane would renormalize it. Stress and depression have been connected to decreased 
expression of BDNF (Smith et al., 1995). Furthermore, elevation in hippocampal BDNF 
mRNA levels have been consistently reported after ECS (Nibuya et al., 1995; Smith et al., 
1997). In line with behavioral observations, we observed no differences in BDNF expression 
in PFC or HC between treatment groups or endophenotypes, as measured by ELISA (Figure 
10). Interestingly, our administration protocol consistently induced cortical TrkB signaling 




Figure 10. BDNF protein levels remained unaltered in PFC and HC in response to CMS 
and repeated isoflurane treatments. Data are presented as mean ± SEM. Figure reprinted 
and modified from publication II. 
 
5.3. Nitrous oxide evokes TrkB signaling and slow-wave EEG 
activity after its acute pharmacological effects have subsided (III) 
 
Like ketamine, N2O is an NMDAR antagonist that has been shown to alleviate depressive 
symptoms in a subset of patients (Nagele et al., 2015). In study III, we wanted to determine 
the effects of N2O on biochemical and electrophysiological markers indicated in the rapid 
antidepressant effects of ketamine. Our specific focus in the biochemical experiments was on 
TrkB signaling and activity-dependent IEGs implicated in antidepressant effects. We took 
advantage of the fast pharmacokinetic properties of N2O, which allowed us to investigate the 
temporal regulation of these effects both during and after the acute drug-induced NMDAR 
blockade. The period after the acute effects is particularly interesting, since the antidepressant 
effects of ketamine are known to emerge preferentially after the psychotomimetic effects 
subside (Zarate et al., 2006a). 
 
To test whether subanesthetic doses of ketamine and N2O share the ability to induce EEG slow-
wave activity (SWA) similarly to ECT, we measured the effects of these treatments on mouse 
EEG across the drugs’ acute effects and withdrawal. As previously reported, a subanesthetic 
dose of ketamine (10 mg/kg, i.p.) caused an acute increase in EEG gamma oscillations (25–
100 Hz) for approximately 30–50 minutes (Figure 11A) (Hiyoshi et al., 2014). After these 
acute effects subsided, we observed a gradual increase of slow-wave delta oscillations (1–4 
Hz) that exceeded those observed in the saline-treated control group. With N2O (50% in O2 for 
1 h), we discovered a general dampening of EEG power for the whole duration of treatment 
(Figure 11B). After terminating the gas flow, however, we observed a gradual increase of 












































Figure 11. Ketamine and nitrous oxide cause a “rebound” increase in delta EEG power 
after acute pharmacological effects subside. Normalized EEG power of main oscillations 
and representative time-frequency spectrogram after (A) ketamine (10 mg/kg, i.p., 100 min) 
and (B) N2O (50% in O2, 60 min + 60 min washout) administration. Data are presented as 
mean ± SEM. Figure reprinted and modified from publication III. 
 
Next, we wanted to examine whether N2O induces rapid cortical excitation. We adopted the 
treatment protocol from the proof-of-concept clinical study by Nagele et al. (2015) and 
exposed animals to 50% N2O for one hour in an anesthesia chamber. The animals were allowed 
a one-hour recovery in their home cage before collection of PFC samples. Expressions of 
activity-dependent IEGs were assayed with quantitative real-time PCR. The levels of IEG 
(e.g., Arc, Bdnf, c-fos) mRNAs were upregulated after N2O exposure (Figure 12A). To 
differentiate whether the effect emerges during gas administration or upon gas withdrawal, we 
then collected samples after 2 hours of continuous 50% N2O administration and one hour after 
a 1-hour exposure. The upregulation of the examined IEGs was still evident in both groups 
(Figure 12B), indicating that excitatory activity takes hold during gas administration. 
Furthermore, we wanted to test whether shorter durations of gas exposure would be sufficient 
to upregulate excitatory markers. Indeed, phosphorylation of MAPK and expression of c-fos 
were upregulated after only a 30-minute exposure to N2O (Figure 12C). 
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Figure 12. Nitrous oxide upregulates activity-dependent immediate-early genes. (A) 
Expression of Arc, Bdnf, c-fos, Egr-2, Homer1a, Mkp1, Synapsin I, and Zif268 mRNA after 1-
hour exposure to 50% N2O and 1-hour washout in mouse PFC. (B) Arc, Bdnf, and c-fos mRNA 
are similarly upregulated after a 2-hour continuous N2O administration (50% in O2) and after 
a 1-hour washout following a 1-hour administration in mouse PFC. (C) A 30-minute 
continuous administration of N2O (50% in O2) upregulates c-fos mRNA and MAPK 
phosphorylation in mouse PFC. Data are presented as mean ± SEM. *< 0.05, **< 0.01, ***< 
0.001, Student’s/Welch’s t-test (A, C) and Kurskal-Wallis one-way ANOVA followed by 
Dunn’s post hoc test/one-way ANOVA, followed by Dunnett’s post hoc test (B). Figure 
reprinted and modified from publication III. 
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To test whether N2O activates TrkB signaling, we collected cortical samples immediately after 
a 30-minute administration of 50% N2O. We assayed phosphorylation of TrkB, GSK3β, and 
p70S6K via Western blotting but observed no regulation, indicating that ongoing NMDAR 
blockade is not directly associated with activation of TrkB signaling (Figure 13A). However, 
in samples that were collected after N2O exposure, during rebound SWA, TrkB signaling was 
significantly increased in all used N2O concentrations (50%, 65%, 75%) (Figure 13B). Since 
65% N2O caused the largest increase in TrkB signaling, we used that concentration to test 
whether the signaling events are maintained at further time points. Indeed, the signaling was 
still upregulated 15 minutes after gas cessation (Figure 13C). 
Figure 13. Dose- and time-dependent TrkB signaling effects of nitrous oxide. (A) 
Phosphorylation of TrkB, GSK3β, and p70S6K in mouse PFC remains unaltered during acute 
effects of 50% N2O. (B) TrkB signaling is upregulated after a 5-minute washout from different 
N2O concentrations. (C) Upregulation of TrkB signaling is maintained 15 minutes after 
treatment discontinuation of 65% N2O. Data are presented as mean ± SEM. *< 0.05, **< 0.01, 
***< 0.001, Student’s/Welch’s t-test (A,B) and Mann-Whitney test (C). Figure reprinted and 
modified from publication III. 
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To model ECT in rodents, we administered a volatile convulsant flurothyl on a cotton pad 
attached to the lid of an airtight Plexiglas chamber (10%, 100 μl/min) until the animals 
expressed generalized seizure behavior. The seizure was terminated by removing the chamber 
lid and attached cotton pad. A rapid emergence of SWA was observed after a chemically 
induced seizure by flurothyl (Figure 14A). TrkB signaling was robustly upregulated 10 
minutes after the seizure (Figure 14B).  
 
Figure 14. Flurothyl-induced seizure is followed by rebound SWA and TrkB signaling. 
(A) Normalized EEG power of main oscillations and representative time-frequency 
spectrogram after flurothyl-induced seizure. (B) TrkB signaling is upregulated during SWA 
10 minutes after seizure. Data are presented as mean ± SEM. *< 0.05, ***< 0.001, Student’s 
t-test. Figure reprinted and modified from publication III. 
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Next, we wanted to test whether a more direct pharmacological induction of SWA would also 
upregulate TrkB signaling. A systemic administration of sedative α2-adrenergic agonist 
medetomidine (0.05–0.3 mg/kg, i.p.) had no effect on activity-dependent IEG expression but 
robustly increased EEG SWA and phosphorylated TrkB, GSK3β, and p70S6K in PFC 30 
minutes after administration (Figure 15A–B). 
 
Figure 15. Medetomidine induces EEG SWA and TrkB signaling. (A) Spectral EEG 
power, major EEG oscillation frequency band power, represented as area under curve (AUC), 
and representative time-frequency spectrograms after 30 minutes of saline (SAL, i.p.) or 
medetomidine (MED, 0.3 mg/kg, i.p.) injections. (B) Medetomidine (0.05 mg/kg, i.p.) 
increases phosphorylation of TrkB, GSK3β, and p70S6K 30 minutes after treatment in mouse 
PFC. Data are presented as mean ± SEM. *< 0.05, **< 0.01, ***< 0.001, Student’s/Welch’s 
t-test. Figure reprinted and modified from publication III. 
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To see whether medetomidine’s robust regulation of TrkB signaling would be reflected in an 
antidepressant-like effect similar to that produced by ketamine, we subjected mice to the 
learned helplessness model of depression. The animals that expressed the helpless phenotype 
after repeated exposures to foot shocks were administered saline, ketamine (10 mg/kg, i.p.), or 
medetomidine (0.05 mg/kg, i.p.), and the changes in helpless behavior were assessed 24 hours 
after treatment administrations. Unlike ketamine, medetomidine elicited no antidepressant-like 
response, as measured in failures to escape foot shocks, indicating that induction of TrkB 
signaling per se is not sufficient to elicit a rapid antidepressant-like behavioral response 
(Figure 16). 
Figure 16. Ketamine—but not medetomidine—alleviates learned helplessness behavior 
in mice. Number of escape failures in a learned helplessness trial before and 24 hours after 
saline (SAL, i.p.), ketamine (KET, 10 mg/kg, i.p.), and medetomidine (MED, 0.05 mg/kg, i.p.) 
administrations. Ketamine caused a significant reduction in the number of escape failures, 
whereas medetomidine did not elicit similar antidepressant-like effects despite its ability to 
induce TrkB signaling. Data are presented as mean ± SEM. **< 0.01, Kruskal-Wallis one-way 
ANOVA. Figure reprinted and modified from publication III. 
 
5.4. Ketamine dose-dependently increased TrkB signaling, 
independently of its HNK metabolites (IV) 
 
Ketamine elicits its antidepressant-like effects particularly in subanesthetic doses, whereas 
higher anesthetic doses are considered inefficient (Li et al., 2010). However, in light of our 
finding of the sedative drug medetomidine’s ability to elicit TrkB signaling, we were interested 
whether ketamine’s ability to induce similar signaling effects would vary dose-dependently. 
In addition, a recent study proposed a metabolite of ketamine, HNK, to be responsible for 
ketamine’s antidepressant effects, raising the question of whether HNK would also be 
responsible for ketamine-induced signaling effects (Zanos et al., 2016). In the fourth study, we 
investigated the dose-dependent effects of ketamine on EEG and TrkB signaling and 
determined whether the signaling effects are regulated by the HNK metabolite.  
 46 
First, we tested the differential effects of subanesthetic (10 mg/kg, i.p.) and anesthetic (100 
mg/kg, i.p.) doses of ketamine on mouse EEG. Subanesthetic ketamine caused a rapid increase 
in high frequency gamma oscillations (60–100 Hz) while lacking any major effects on other 
frequency bands during the 30-minute recording period (Figure 17). The anesthetic dose 
rapidly induced delta activity (1–4 Hz) while also modestly increasing theta (4–7 Hz), beta 
(12–25 Hz), and gamma oscillations (low: 25–40 Hz; high: 60–100 Hz) and decreasing alpha 
(7–12 Hz) oscillations.  
 
 
Figure 17. Effects of subanesthetic (10 mg/kg, i.p.) and anesthetic (100 mg/kg, i.p.) doses 
of ketamine on mouse EEG. (A) Normalized power of main EEG oscillations 30 minutes 
after ketamine administration (i.p.). (B) Major EEG oscillation frequencies as area under curve 
(AUC) representations for a 30-minute duration after treatment administration. Figure 








Next, we tested the effects of ketamine and HNK on TrkB signaling. An anesthetic (100 mg/kg, 
i.p.)—but not subanesthetic (10 mg/kg, i.p.)—dose of ketamine upregulated phosphorylation 
of TrkB, GSK3β, and p70S6K in mouse PFC 30 minutes after administration (Figure 18A), 
indicating that ketamine regulates TrkB signaling dose-dependently. This finding was 
supported by our findings of a dose-dependent regulation of TrkB signaling with two 
additional doses of ketamine (50 mg/kg and 200 mg/kg, i.p.) (Figure 18B). 
 Figure 18. Ketamine dose-dependently upregulates TrkB signaling in mouse PFC. (A, 
B) Ketamine dose-dependently upregulates phosphorylation of TrkB, GSK3β, and p70S6K. 
Medial PFC samples were collected 30 minutes after i.p. injections. Data are presented as mean 
± SEM. *< 0.05, **< 0.01, Kruskal-Wallis one-way ANOVA followed by Dunn’s post hoc 
test (A) and one-way ANOVA followed by Dunnett’s post hoc test (B). Figure reprinted and 
modified from publication IV. 
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To further examine the relevance of ketamine metabolism to its effect on TrkB signaling, we 
tested the effects of systemic cis-HNK administration (20 mg/kg, i.p.) on TrkB signaling. 
Furthermore, we synthesized a deuterated form of ketamine (6,6-dideuteroketamine). 
Ketamine deuterated at the C6 position has a decreased rate of metabolism to HNK. No 
signaling effects were observed 30 minutes after cis-HNK administration (Figure 19A), 
whereas deuterated ketamine (100 mg/kg, i.p.) upregulated phosphorylation of TrkB, GSK3β, 
and p70S6K in mouse PFC 30 minutes after administration similarly to ketamine (Figure 
19B), indicating that ketamine’s ability to induce TrkB signaling is independent of its 
metabolism to HNK. 
Figure 19. (A) Cis-6-hydroxynorketamine (HNK, 20 mg/kg, i.p.) caused negligible effects on 
TrkB signaling. (B) Deuteroketamine (d-KET, 100 mg/kg, i.p.) regulates phosphorylation of 
TrkB, GSK3β, and p70S6K similarly to ketamine (100 mg/kg, i.p.). Mouse PFC samples were 
collected 30 minutes after administration. Data are presented as mean ± SEM. *< 0.05 One-
way ANOVA followed by Dunnett’s post hoc test. Figure reprinted and modified from 
publication IV. 
 
Overall, our findings show that ketamine preferentially regulates TrkB signaling in higher, 
anesthetic doses and that the signaling effects are not dependent on ketamine’s metabolism to 
HNK. In addition, our findings show that ketamine-induced TrkB signaling is associated with 




Anesthetics are strong modulators of excitatory and inhibitory neurotransmission. While 
mainly used in surgical operations, anesthetics have relatively recently gained wider interest 
in their potential in the treatment of mood disorders. Subanesthetic ketamine, in particular, has 
demonstrated remarkably rapid antidepressant features, but other anesthetic agents, such as 
isoflurane, N2O, and propofol have shown promise as well (Berman et al., 2000; Langer et al., 
1995; Mickey et al., 2018; Nagele et al., 2015; Weeks et al., 2013). Despite this, accumulating 
knowledge of anesthetic function has raised serious concerns over the drugs’ potentially 
detrimental effects on the developing brain (Jevtovic-Todorovic et al., 2003). In the present 
thesis, we have investigated various aspects of anesthetic function, from the drugs’ potential 
long-lasting adverse effects to their underlying antidepressant mechanisms. 
 
6.1. Developmental stage-dependent effects of early postnatal 
anesthesia 
 
Anesthetics have been consistently shown to have differential effects on the developing 
nervous system in rodents, depending on the specific stage of CNS maturation during 
anesthesia exposure (Briner et al., 2011; Qiu et al., 2016). Repeated exposure to anesthetics 
during early postnatal development has been associated with learning deficits later in life 
(Flick et al., 2011; Wilder et al., 2009). These findings are supported by experimental evidence 
in rodents demonstrating that early postnatal anesthesia increases apoptotic neurodegeneration 
(Jevtovic-Todorovic et al., 2003; Tagawa et al., 2014). In contrast, anesthesia during the third 
postnatal week in rodents has been shown to increase dendritic spine density (Briner et al., 
2010; De Roo et al., 2009). However, the long-term physiological significance of these 
alterations, and the relevance for the depth and duration of anesthesia remain poorly 
elucidated. Deleterious effects of early-life anesthesia would have significant clinical 
implications due to the widespread use of anesthetics for surgical anesthesia, mild sedation, 
and analgesia in pediatric medicine. Furthermore, along with the continuous advances in 
modern preclinical invasive techniques (e.g., in vivo imaging), the use of anesthetics is steadily 
growing in veterinary medicine and biomedical research involving animals, and any permanent 
effects that anesthesia may have beyond its acute effects pose a significant confounding factor 
in the interpretation of these experimental findings. In light of the differential effects of early-
life anesthesia, we hypothesized that repeated isoflurane anesthesia administered at different 
developmental time points would have differing effects on adult behavior. 
 
In the first study of the present thesis, a 30-minute isoflurane anesthesia on three consecutive 
days at two distinct time points during early development caused modest effects in adult 
behavior. These behavioral alterations, observed in overall locomotor activity, spatial learning, 
and memory, were dependent on the time points of exposure to anesthesia or maternal 
separation. Our findings are in line with a recent study that demonstrated negligible long-
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lasting behavioral effects of a brief early-life anesthesia with sevoflurane (Qiu et al., 2016). 
Duration of anesthesia may play a significant role since a 6-hour anesthesia has been shown 
to have detrimental long-lasting consequences (Briner et al., 2011). Further, repeated 
sevoflurane anesthesia (3 x 2 hours) caused more significant synapse loss than a single 6-hour 
anesthesia (Amrock et al., 2015). Therefore, it is plausible to speculate that a longer exposure 
to isoflurane anesthesia may produce more noticeable behavioral effects than those observed 
in our study. 
 
A rodent brain goes through rapid and fundamental changes between the first and second 
postnatal weeks—during the brain growth spurt and critical period—which may help in 
explaining the differential effects of anesthetics at different developmental time points (Clancy 
et al., 2001). For instance, the function of GABAergic neurotransmission, a major target of 
anesthetic function, changes from depolarizing to hyperpolarizing due to developmental 
changes in intracellular Cl- concentration, brought about by gradual upregulation of neuronal 
potassium-chloride cotransporter KCC2 expression during brain maturation (Rivera et al., 
1999). 
 
One limitation of the study is that no measurements of apoptotic markers or dendritic spine 
density were made following our anesthesia regimen, therefore limiting the conclusions that 
can be drawn from our data. Our study focuses on general behavioral phenomena in canonical 
behavioral tests, but the molecular events associated with the potential long-term deleterious 
effects of isoflurane remain to be elucidated. Furthermore, despite our use of a wide behavioral 
battery, some subtler deficits not addressed in our test battery may still remain unnoticed. 
Translational extrapolation of our results to humans are limited due to major differences in the 
progress of brain development between species and the limited applicability of the behavioral 
phenotype of rodents to humans (Clancy et al., 2001). None of the selected behavioral tests 
can fully recapitulate human diseases but may reveal phenotypical characteristics that 
resemble certain pathological states (e.g., the prepulse inhibition test for schizophrenia). 
 
As of now, conflicting evidence exists regarding the long-term harms of early-life anesthesia 
(Yu et al., 2013). Anesthetics provide the means to perform surgical operations whose benefits 
may far outweigh the potential deleterious effects of anesthesia, but currently available data 
advises caution and consideration, especially for repeated anesthesia exposures during 
childhood and adolescence. The exposure duration likely plays a significant role in the 
potential detrimental effects of anesthesia since a recent clinical trial demonstrated that just 
under an hour of general anesthesia during early infancy caused no notable 




6.2. Negligible effects of isoflurane anesthesia in the rat CMS 
model 
 
In study II, we tested the antidepressant-like effects of repeated isoflurane anesthesia on a rat 
CMS model. Isoflurane has been shown to alleviate depressive symptoms in preliminary 
clinical trials, but many subsequent findings have remained contradictory (Greenberg et al., 
1987; Langer et al., 1985, 1995). Recent clinical and preclinical studies demonstrating the 
antidepressant potential of isoflurane have renewed interest in the study of isoflurane in an 
antidepressant context (Antila et al., 2017; Brown et al., 2018a; Weeks et al., 2013). However, 
in our experiment, repeated isoflurane anesthesia failed to alleviate anhedonic behavior in rats 
exposed to CMS. This lack of effect was accompanied by—and potentially connected to—a 
lack of regulation of cortical and hippocampal BDNF expression. Our findings therefore 
provide no direct support for the antidepressant potential of isoflurane anesthesia per se. 
However, the optimal dose and duration of isoflurane “narcotherapy,” as coined by Langer and 
colleagues (1995), remain largely unknown. Preclinical and clinical studies have demonstrated 
an antidepressant-like efficacy of isoflurane with various administration protocols (Antila et 
al., 2017; Brown et al., 2018a; Langer et al., 1995; Weeks et al., 2013). In a recent study, Zhang 
and colleagues (2019) demonstrated that only a single isoflurane anesthesia for 30 minutes (4–
3% induction, 2% maintenance) renormalized behavioral deficits induced by CMS in mice. 
BDNF expression in the PFC was also shown to be decreased after CMS and renormalized to 
basal levels after isoflurane administration, indicating that the antidepressant potential of 
isoflurane may be connected to an administration routine that induces BDNF upregulation. 
Our findings conflict with these observations, which may be due to our use of a highly stress-
sensitive substrain of rats that are resistant to citalopram after CMS exposure (Neyazi et al., 
2018). Unaltered BDNF levels after isoflurane anesthesia, however, have also been reported, 
indicating a degree of unpredictability in isoflurane’s capability to influence BDNF expression 
(Antila et al., 2017).  
 
It is also debatable whether the CMS model is a sufficient method of modeling clinical 
depression in rodents. Although the validity of the CMS model is relatively strong as the 
behavioral phenotype includes many aspects reminiscent of a depressive state, including 
anhedonia, sleep pattern disturbances, weight loss, and decrease in motivated behaviors, some 
discrepancies remain (Willner, 2017). The depression-like symptoms, namely anhedonia, as 
measured by sucrose consumption, quickly return to basal level once the mild stressors are 
stopped, whereas major depression in humans is usually more persistent (Grippo et al., 2003). 
In addition, the CMS model has raised controversy due to its poor reproducibility, which was 
evident in our study as well since only 53.8% of the stress-exposed rats developed the 
anhedonic phenotype (Krishnan & Nestler, 2011). Similar shortcomings in symptom 
persistency and reproducibility are also associated with the learned helplessness model used 
in study III. Nevertheless, depressive-like behaviors, such as anhedonia, behavioral despair, 
and helplessness, in rodents can be consistently renormalized with antidepressants (Willner, 
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2017). However, these treatment responses are mainly observed with conventional 
monoaminergic antidepressants, and their responsiveness to novel non-monoaminergic drugs 
remains to be clarified. 
 
6.3. Increased TrkB signaling during rebound SWA—a primer 
for a shared mechanism of rapid-acting antidepressants? 
 
In studies III and IV, we aimed to gain more insight into the neurobiological mechanisms 
underlying rapid antidepressant effects by examining the EEG and molecular effects of 
antidepressant anesthetics, such as N2O and ketamine. N2O has been shown to alleviate 
depressive symptoms in a small-scale clinical trial, but the molecular mechanisms related to 
these effects are still rarely studied (Nagele et al., 2015). N2O would have several clinical 
benefits over ketamine if its antidepressant potential proves plausible. The administration of 
N2O can be easily controlled due to its fast pharmacokinetics and negligible metabolism. The 
acute effects of N2O emerge within seconds of administration and cease within minutes of 
treatment discontinuation (Nagele et al., 2018). However, the misuse potential and adverse 
effects of N2O must be taken into consideration (van Amsterdam et al., 2015). Heavy and 
repeated use of N2O has also been associated with vitamin B12 deficiency. 
 
By taking advantage of the rapid pharmacokinetic properties of N2O, we discovered that N2O 
induces an emergence of EEG SWA that is coupled with upregulation of TrkB signaling in 
mouse PFC. This effect emerges only after drug discontinuation. The acute effects of N2O, in 
contrast, were characterized by the upregulation of activity-dependent IEGs, but effects on 
TrkB signaling remained negligible. A similar phenomenon of rebound SWA, coupled with 
increased TrkB signaling, were observed after seizures chemically induced by a volatile 
convulsant, flurothyl. However, direct induction of SWA by the sedative drug medetomidine 
proved ineffective in producing an antidepressant-like response in the learned helplessness 
model even though it readily upregulated TrkB signaling. 
 
Furthermore, in study IV, we also demonstrated that ketamine induces TrkB signaling during 
SWA. These effects were not limited to subanesthetic doses but rather were more pronounced 
with higher, anesthetic doses. We also found these signaling effects to be independent of 
ketamine’s metabolism to HNK. However, the conclusions that can be drawn on the ability of 
HNK to initiate TrkB signaling based on our current study are limited. In our study, we 
examined the signaling effects of HNK only in a single dose and time point post-
administration, and focused on changes in the PFC. Our study does not, therefore, rule out the 
possibility that HNK might elicit signaling responses similar to ketamine in other doses, time 
points, or brain regions.  
 
Overall, these findings indicate that TrkB signaling, although likely a crucial component of 
rapid antidepressant responses, as indicated by a lack of antidepressant effects of ketamine in 
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conditional Bdnf-/- rodents (Autry et al., 2011), is not in itself sufficient to elicit a rapid 
antidepressant response. Instead, N2O, flurothyl, and subanesthetic ketamine share the 
capability to induce cortical excitation before the effects on TrkB signaling emerge. Based on 
these findings, we have formulated a hypothesis of the two phases of rapid antidepressant 
action (Kohtala, 2019) (Figure 20A). The hypothesis proposes that for a drug to function as a 
rapid-acting antidepressant, it must elicit an initial phase of transient cortical excitation that 
can be characterized, for instance, by upregulation of activity-dependent IEGs or MAPK 
phosphorylation, or an increase in EEG gamma oscillations. This excitatory phase is followed 
by a subsequent sedative-like state, during which SWA emerges alongside neurotrophic 
signaling. 
 
In regular physiological conditions, BDNF is expressed as a response to neuronal activity (Park 
& Poo, 2013; Thoenen, 1995). Global cortical excitation is evident during seizure 
manifestation in ECT and is correspondingly shown to increase BDNF expression (Altar et al., 
2003, 2004; Angelucci et al., 2002; Nibuya et al., 1995), but the importance of postictal EEG 
silencing in ECT’s therapeutic effect has also been emphasized (Nobler et al., 1993; Sackeim 
et al., 1996; Suppes et al., 1996). Isoflurane shares the capability to produce electrocerebral 
silence with ECT but without the preceding seizure activity (Langer et al., 1995). However, 
excitatory responses have been reported in association with isoflurane anesthesia, particularly 
during anesthesia induction and emergence, when the concentration of the anesthetic is low 
(Voss et al., 2008). In rodents, isoflurane produced hyperactivity during anesthesia induction, 
while in rodent brain slices, low isoflurane concentrations enhanced neuronal excitability 
(Becker et al., 2012; Ou et al., 2020). In clinical practice, a state of restless, agitated, and 
incoherent behavior is well-recognized during the induction and emergence of anesthesia with 
several general anesthetics, including isoflurane (Costi et al., 2014; Moore & Anghelescu, 
2017). Interestingly, an increased plasma BDNF level has been shown to correlate with 
emergence agitation in elderly patients after propofol-induced anesthesia (Mei & Tong, 2016). 
In addition to anesthesia induction and emergence, cortical hyperexcitability has been reported 
during deep burst-suppressing anesthesia (Ferron et al., 2009; Kroeger & Amzica, 2007). 
Therefore, it is tempting to speculate that an administration regimen capable of producing 
cortical excitation and an accompanying BDNF upregulation may provide a more robust 
antidepressant-like effect. The present hypothesis would account for the lack of antidepressant-
like effects of isoflurane anesthesia since it may not consistently induce similar biphasic 
actions (Figure 20B). Further studies to clarify the antidepressant potential of isoflurane in 




Figure 20. Hypothesis of biphasic effects of rapid-acting antidepressants. (A) Our findings 
suggest that rapid-acting antidepressants share the capability to induce cortical excitation, as 
exemplified by upregulation of activity-dependent immediate-early genes during the acute 
drug effects (left panel), and to induce slow-wave EEG activity accompanied by upregulated 
TrkB signaling after the peak pharmacological effects subside (right panel). (B) According to 
the hypothesis, isoflurane may lack antidepressant-like effects in dosing that produces 
insufficient excitatory response. However, isoflurane may exert paradoxical cortical excitation 




The functional significance of the biphasic actions observed with N2O, subanesthetic ketamine, 
and flurothyl remains to be elucidated. Interesting hints may, however, be offered by the 
physiology of sleep since the EEG SWA pattern that we observed after treatment 
discontinuation is also characteristic of deep non-rapid eye movement (NREM) sleep. A 
prominent hypothesis of sleep, the synaptic homeostasis hypothesis (SHY), postulates that 
NREM sleep SWA increases as a function of preceding synaptic potentiation during 
wakefulness and represents a phase of downscaling of synaptic strength (Tononi & Cirelli, 
2003). This downscaling allows for the maintenance of synaptic homeostasis so that saturation 
of synaptic connections is avoided and headroom for synaptic plasticity and learning is 
maintained. It is therefore tempting to speculate that similar homeostatic mechanisms may 
apply to rapid-acting antidepressant function as well. Indeed, ketamine has been shown to 
increase SWA in the night following the administration in both humans and rodents (Duncan 
et al., 2013; Feinberg & Campbell, 1993). The increase in ketamine-induced sleep SWA was 
also reported to be proportional to an increase in plasma BDNF levels in treatment responders 
(Duncan et al., 2013). Intriguing similarities have also been observed with sleep deprivation, 
a somatic treatment for depression that has been shown to induce cortical excitability during 
prolonged wakefulness, followed by increased SWA during the recovery sleep period 
(Campbell & Feinberg, 1999; Huber et al., 2000, 2013). Since we found SWA and TrkB 
signaling to emerge only after the acute pharmacological effects of the treatments subside, it 
is plausible to hypothesize that these phenomena are an inherent response of the brain to an 
excitatory challenge, regardless of whether it is mediated by an excitatory drug such as N2O 
or ketamine, a generalized seizure induced by ECT or flurothyl, or through prolonged 
wakefulness. 
 
Indeed, a recent proposal suggests the initial phase of cortical excitation during the acute 
effects of rapid-acting antidepressants represents a phase of increased synaptic potentiation 
through molecular mechanisms reminiscent of LTP, including rapid transcription of plasticity-
related IEGs, such as Arc and Bdnf (Rantamäki & Kohtala, 2020). These changes ultimately 
lead to acute changes in the functional connectivity of neural networks, but the effects would 
remain transient without further consolidation. In accordance with the SHY hypothesis, the 
homeostatic emergence of SWA and accompanying molecular signaling mechanisms 
following the acute effects of rapid-acting antidepressants may reflect a subacute consolidation 
of synaptic changes induced by the acute excitatory effects of the investigated anesthetics, and 
ultimately contribute to the reconfiguration of functional network connectivity, which is 
pathologically altered in depression (Rantamäki & Kohtala, 2020). Essentially, our findings 
suggest that reproducing this biphasic phenomenon may be more important than the 
treatment’s engagement of an acute pharmacological target in mediating rapid antidepressant 
responses. This is further supported by the mechanistic diversity of rapid-acting antidepressant 
treatments, which range from the NMDAR antagonism of ketamine and N2O to non-
pharmacological treatments, such as ECT and sleep deprivation, and potentially to the 
serotonergic agonism of classical psychedelics.  
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The findings linking rebound EEG SWA and increased TrkB signaling in studies III and IV 
remain largely correlational. However, the present hypothesis provides a novel framework for 
additional clinical and preclinical studies that encourages widening the perspective of 
mechanistic antidepressant studies from the acute pharmacology of the given treatment to the 
adaptive changes and homeostatic responses of the brain to a drug challenge. The importance 
of further studies on the mechanisms of rapid-acting antidepressants is emphasized by the 
recent approval of intranasal esketamine as an adjunct for oral antidepressants for treatment-
resistant depression in adults in the US and Europe. This will likely increase clinical use of 
ketamine in the coming years. Our findings indicate that a subanesthetic bolus of ketamine 
may be sufficient to reproduce the biphasic effect observed in our studies, but this effect needs 
to be confirmed in human studies and in an intranasal administration route. The increasing 
clinical use of ketamine also calls for strategies to mitigate the risks of its adverse effects and 
misuse potential. Such strategies currently include special regulations and monitoring, such as 





























In this thesis, I examined the behavioral and molecular effects of various anesthetics indicated 
to have rapid-acting antidepressant potential. The findings presented here demonstrate a shared 
phenomenon in EEG and TrkB signaling between pharmacologically diverse rapid-acting 
antidepressants. 
 
The main conclusions are: 
 
I  Repeated exposure to brief but deep isoflurane anesthesia during postnatal days 7–9 
or 15–17 causes minor effects on the general locomotor activity, spatial learning, and 
memory in adult male mice. The behavioral effects are dependent on the 
developmental time point of anesthesia exposures. 
 
II  Repeated exposure to brief but deep isoflurane anesthesia lacks antidepressant-like 
effects in the chronic mild stress model in adult rats. The lack of behavioral effects is 
consistent with unchanged levels of cortical and hippocampal BDNF expression. 
 
III  Nitrous oxide and subanesthetic ketamine induce EEG slow-wave activity after their 
peak pharmacological effects subside, resembling postictal silencing following 
electroconvulsive therapy or volatile convulsant flurothyl. The slow-wave activity is 
accompanied by upregulation of TrkB signaling. 
 
IV Medetomidine does not produce antidepressant-like effects in the learned 
helplessness model of depression in mice despite readily upregulating slow-wave 
activity and TrkB signaling. 
 
V  Ketamine induces TrkB signaling dose-dependently. The effects are independent of 
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